Chimeric polypeptides

By designing chimeric or fusion proteins with specific amino acid sequence modifications, the existing technical challenges of immune response to Porphyromonas gingivalis infection have been solved, improving solubility and stability, enhancing immunogenicity, and achieving effective prevention and treatment of Porphyromonas gingivalis infection.

CN118922203APending Publication Date: 2024-11-08DANTREK GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027379.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-20
Filing Date
2023-01-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is a lack of effective methods in the current technology to induce a strong protective immune response to prevent or treat Porphyromonas gingivalis infection. Furthermore, existing chimeric or fusion proteins have poor solubility and stability during large-scale preparation and have a serious tendency to polymerize, which affects the effectiveness of the immune response.

Method used

A chimeric or fusion protein was designed, comprising the active site and adhesin domain of *Porphyromonas gingivalis* Arg-gingival protease or Lys-gingival protease. Specific amino acid sequence modifications were used to reduce the tendency to polymerize, improve solubility and stability, and the full-length DUF2436 domain was employed to enhance the production of soluble recombinant proteins.

Benefits of technology

It improves the solubility and stability of chimeric or fusion proteins, reduces polymerization, enhances immunogenicity, facilitates large-scale preparation, effectively induces protective immune responses, and reduces the severity of Porphyromonas gingivalis infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005041071940000181
    Figure BDA0005041071940000181
  • Figure BDA0005041071940000191
    Figure BDA0005041071940000191
  • Figure BDA0005041071940000201
    Figure BDA0005041071940000201
Patent Text Reader

Abstract

A chimeric or fusion protein for use in inducing an immune response to Porphyromonas gingivalis (P. gingivalis), the protein comprising a first polypeptide linked to a second polypeptide, wherein: A) the first polypeptide comprises or consists of an amino acid sequence of an active site of Arg-gingival protease or Lys-gingival protease of Porphyromonas gingivalis, or a sequence at least 80% identical to the amino acid sequence of the active site of Arg-gingival protease or Lys-gingival protease of Porphyromonas gingivalis; and B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingival protease or Lys-gingival protease of Porphyromonas gingivalis; and wherein: a) the second polypeptide comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of the Arg-gingival protease or Lys-gingival protease, or a sequence at least 80% identical thereto; and / or b) the second polypeptide comprises one or more cysteine amino acid substitutions in the adhesin domain as compared to the naturally occurring Arg-gingival protease or Lys-gingival protease sequence in the corresponding region; and the second polypeptide optionally comprises one or more amino acid motif substitutions in the adhesin domain to reduce multimerization.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to chimeric polypeptides that can be used to induce an immune response to Porphyromonas gingivalis (P. gingivalis), compositions comprising the chimeric polypeptides, and uses thereof for preventing and treating P. gingivalis-associated conditions and diseases.

[0002] Related Applications

[0003] This application claims priority from Australian provisional application AU 2022900103, the entire contents of which are hereby incorporated by reference. Background Art

[0004] If plaque accumulates around the teeth at the gingival (gingival or gum) margins, it can cause inflammation of the gums (gingivitis). Chronic gingivitis can allow the periodontal pathogen Porphyromonas gingivalis (P. gingivalis) to settle in the base of the periodontal pockets, leading to chronic infection and development of severe disease. This severe periodontal disease is called periodontitis and can lead to tooth loss through the immune system's efforts to eliminate the infection.

[0005] Chronic periodontitis is an inflammatory disease of the supporting tissues of the teeth, leading to resorption of alveolar bone and eventual tooth loss. The disease is a major public health problem in all societies and is estimated to affect up to 30% of the adult population, with severe forms affecting 12-15% of the adult population.

[0006] One-third of adults suffer from moderate to severe periodontitis. According to epidemiological surveys, periodontitis is associated with an increased risk of inflammatory diseases (including cardiovascular disease, certain cancers, premature birth, rheumatoid arthritis and dementia). Recent studies have linked chronic infection with Porphyromonas gingivalis to dementia and rheumatoid arthritis. For example, in one study, 96% of Alzheimer's disease (AD) brain samples showed the presence of Porphyromonas gingivalis. Another study showed that chronic oral infection of mice with Porphyromonas gingivalis caused brain plaques associated with human AD, and that Porphyromonas gingivalis proteases can cleave amyloid precursors and tau proteins to form plaques and tangles associated with AD.

[0007] A number of virulence factors have been reported to contribute to the pathogenicity of P. gingivalis, including: LPS, fimbriae, hemagglutinins, hemolysins, and extracellular hydrolases (especially Arg-X and Lys-X specific proteases), also known as "P. gingivalis gingipains".

[0008] The importance of the public health problem creates a need for a vaccine that provides a strong protective response to Porphyromonas gingivalis infection and methods of providing the same.

[0009] One problem is that it is unclear how to obtain a strong protective response to P. gingivalis infection when there are a plethora of virulence factors to choose from.

[0010] There are currently no commercially approved vaccines for preventing or reducing the incidence and / or severity of Porphyromonas gingivalis infection, or for treating Porphyromonas gingivalis infection and disease in a subject.

[0011] Therefore, there is a need for alternative and / or improved methods for designing and preparing Porphyromonas gingivalis vaccines, as well as alternative and / or improved vaccines produced by Porphyromonas gingivalis.

[0012] The reference to any prior art in this specification does not constitute an acknowledgement or implication that this prior art forms part of the common general knowledge in any jurisdiction, nor does it mean that this prior art can be reasonably understood by a person skilled in the art, regarded as related to and / or combined with other prior art. Summary of the invention

[0013] The present invention provides a chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis, the protein comprising a first polypeptide and a second polypeptide, wherein:

[0014] A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and

[0015] B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis;

[0016] wherein said second polypeptide comprises a sequence of one or more adhesin binding motifs (ABMs), preferably wherein said ABMs correspond to some or all of said ABMs between the DUF2436 domain and the cleaved adhesin domain (CAD) of Porphyromonas gingivalis gingipain;

[0017] Preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (ABM2) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0018] More preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (ABM2), SEQ ID NO: 14 or 19 (ABM1) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0019] Most preferably wherein the one or more ABMs comprise the sequence shown in any one of SEQ ID NO: 16 or SEQ ID NO: 18 or 22 or SEQ ID NO: 27, 63 or 64, or a sequence at least 80% identical thereto; and

[0020] wherein the second polypeptide comprises part or all of the sequence of a cleaved adhesin domain (CAD), preferably part or all of the sequence of a CAD having the amino acid sequence shown in SEQ ID NO: 12 or 13 or a sequence at least 80% identical thereto,

[0021] And among them:

[0022] a) the second polypeptide comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain, preferably as shown in SEQ ID NO: 23, or a sequence at least 80% identical thereto; and / or

[0023] b) said second polypeptide comprises one or more cysteine ​​amino acid substitutions in said adhesin domain compared to the naturally occurring Arg-gingipain or Lys-gingipain sequence in the corresponding region; and / or

[0024] c) the second polypeptide comprises one or more amino acid motif substitutions selected from the group consisting of:

[0025] i) substitution of proline and / or asparagine residues in the sequence PxxN corresponding to residues 6 to 9 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at positions equivalent to said residues;

[0026] ii) a substitution of the motif NxFA to SxYQ in the sequence corresponding to residues 2 to 5 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at a position equivalent to said residues;

[0027] iii) the substitution of a second tyrosine residue corresponding to, or equivalent to, the residue at position 5 of SEQ ID NO: 15 or 20 (ABM2) and a tryptophan residue corresponding to, or equivalent to, the residue at position 23 of SEQ ID NO: 14 or 19 (ABM1) into an alanine residue.

[0028] Preferably, the chimeric or fusion protein comprises one or more additional polypeptides, the one or more additional polypeptides comprising the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto or consisting thereof. The one or more additional polypeptides comprising the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or consisting thereof may be located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide or the C-terminus of the second polypeptide. In certain embodiments, there may be at least two additional polypeptides, the at least two additional polypeptides comprising the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto or consisting thereof. In such embodiments, the two additional polypeptides may be located at the N-terminus of the second polypeptide, the C-terminus of the second polypeptide or the N and C-termini of the second polypeptide.

[0029] The one or more additional polypeptides may be linked to the first polypeptide or the second polypeptide of the chimeric or fusion protein, preferably via a linker of no more than 50 amino acids, or directly linked to the first polypeptide or the second polypeptide.

[0030] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0031] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0032] In any embodiment, the amino acid sequence comprising the active site of the Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or consisting of the first polypeptide and the other polypeptide comprise or consist of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences, or wherein the amino acid sequences are identical. The first polypeptide and the other polypeptide can be derived from the active site of a heterologous gingipain (e.g., gingipains from different strains of Porphyromonas gingivalis). The first polypeptide and the additional polypeptide may have amino acid sequences derived from different gingipains (e.g., wherein one of the polypeptides has an amino acid sequence from the active site of Kgp and the other has an amino acid sequence from the active site of Rgp; or alternatively, wherein one of the polypeptides has an amino acid sequence from the active site of RgpA and the other has an amino acid sequence from the active site of RgpB).

[0033] In a first aspect, the present invention provides a chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis, the protein comprising a first polypeptide linked to a second polypeptide, wherein:

[0034] A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and

[0035] B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis;

[0036] wherein said second polypeptide comprises a sequence of one or more adhesin binding motifs (ABMs), preferably wherein said ABMs correspond to some or all of said ABMs between the DUF2436 domain and the cleaved adhesin domain (CAD) of Porphyromonas gingivalis gingipain;

[0037] Preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (ABM2) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0038] More preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (ABM2), SEQ ID NO: 14 or 19 (ABM1) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0039] Most preferably wherein the one or more ABMs comprise the sequence shown in any one of SEQ ID NO: 16 or SEQ ID NO: 18 or 22, or a sequence at least 80% identical thereto;

[0040] And among them:

[0041] a) the second polypeptide comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain, preferably as shown in SEQ ID NO: 23, or a sequence at least 80% identical thereto.

[0042] As used herein, an amino acid sequence substantially corresponding to the full length of a DUF2436 domain, or a sequence that is at least 80% identical thereto, refers to a sequence that accounts for at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the length of the DUF2436 domain of Arg-gingipain or Lys-gingipain.

[0043] In a preferred embodiment, the amino acid sequence of the DUF2436 domain of Arg-gingipain or Lys-gingipain is the sequence shown in SEQ ID NO:23, or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0044] Most preferably, the second polypeptide comprises or consists of the sequence shown in SEQ ID NO: 33, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto. In an alternative embodiment, the second polypeptide comprises the sequence shown in SEQ ID NO: 59, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto. In alternative embodiments, the second polypeptide comprises the sequence shown in SEQ ID NO:61, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0045] Preferably, the chimeric or fusion protein comprises one or more additional polypeptides, the one or more additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto. The one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis may be located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide at the C-terminus of the second polypeptide. The one or more additional polypeptides may be connected to the first polypeptide or the second polypeptide of the chimeric or fusion protein, preferably through a linker of no more than 50 amino acids, or directly connected to the first polypeptide.

[0046] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0047] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0048] In any embodiment, the amino acid sequence comprising the active site of the Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or consisting of the first polypeptide and the other polypeptide comprise or consist of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences, or wherein the amino acid sequences are identical. The first polypeptide and the other polypeptide can be derived from the active site of a heterologous gingipain (e.g., gingipains from different strains of Porphyromonas gingivalis). The first polypeptide and the additional polypeptide may have amino acid sequences derived from different gingipains (e.g., wherein one of the polypeptides has an amino acid sequence from the active site of Kgp and the other has an amino acid sequence from the active site of Rgp; or alternatively, wherein one of the polypeptides has an amino acid sequence from the active site of RgpA and the other has an amino acid sequence from the active site of RgpB).

[0049] In a particularly preferred embodiment of the second aspect of the invention, the chimeric or fusion protein comprises or consists of an amino acid sequence as shown in any one of SEQ ID NO:55, 56, 58 or 60, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0050] In a second aspect of the present invention, the present invention provides a chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis, the protein comprising a first polypeptide and a second polypeptide, wherein:

[0051] A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and

[0052] B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis;

[0053] wherein said second polypeptide comprises the sequence of one or more adhesin binding motifs (ABMs), preferably wherein said ABMs correspond to some or all of said ABMs between the DUF2436 domain and the cleaved adhesin domain (CAD) of Porphyromonas gingivalis gingipain,

[0054] Preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (ABM2) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0055] More preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (ABM2), SEQ ID NO: 14 or 19 (ABM1) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0056] Most preferably wherein the one or more ABMs comprise the sequence shown in any one of SEQ ID NO: 16 or SEQ ID NO: 18 or 22 or SEQ ID NO: 27, 63 or 64, or a sequence at least 80% identical thereto; and

[0057] wherein the second polypeptide comprises part or all of the sequence of a cleaved adhesin domain (CAD), preferably part or all of the sequence of a CAD having an amino acid sequence as shown in SEQ ID NO: 12 or 13 or a sequence at least 80% identical thereto, and wherein:

[0058] a) said second polypeptide comprises one or more cysteine ​​amino acid substitutions in said adhesin domain compared to the naturally occurring Arg-gingipain or Lys-gingipain sequence in the corresponding region; and / or

[0059] b) the second polypeptide comprises one or more amino acid motif substitutions selected from the group consisting of:

[0060] i) substitution of proline and / or asparagine residues in the sequence PxxN corresponding to residues 6 to 9 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at positions equivalent to said residues;

[0061] ii) a substitution of the motif NxFA to SxYQ in the sequence corresponding to residues 2 to 5 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at a position equivalent to said residues;

[0062] iii) the substitution of a second tyrosine residue corresponding to, or equivalent to, the residue at position 5 of SEQ ID NO: 15 or 20 (ABM2) and a tryptophan residue corresponding to, or equivalent to, the residue at position 23 of SEQ ID NO: 14 or 19 (ABM1) into an alanine residue.

[0063] The one or more cysteine ​​amino acid substitutions may be substitutions of a serine residue or a valine residue.Preferably, the one or more cysteine ​​substitutions may include one or more substitutions of a serine residue.

[0064] In certain embodiments, only one cysteine ​​residue can be substituted. In other embodiments, two or three cysteine ​​residues can be substituted. In particularly preferred embodiments, the cysteine ​​residue is substituted with a combination of valine and serine residues. In other embodiments, all substituted cysteine ​​residues are substituted with serine or all substituted cysteine ​​residues are substituted with valine.

[0065] In particularly preferred embodiments, the adhesin domain comprises a DUF2436 domain or a portion thereof, and the cysteine ​​residues in the DUF2436 domain are substituted with serine or valine, preferably serine. In other embodiments, the adhesin domain comprises a DUF2436 domain, and the cysteine ​​residues in the DUF2436 domain are not substituted, and preferably, one or more cysteine ​​residues in the remainder of the adhesin domain are substituted.

[0066] Optionally, the adhesin domain comprises or consists of the sequence shown in SEQ ID NO: 23, or a sequence at least 80% identical thereto, wherein the cysteine ​​residue is substituted with a serine or valine residue.

[0067] Optionally, the adhesin domain comprises or consists of the sequence shown in SEQ ID NO: 25, or a sequence at least 80% identical thereto, wherein the cysteine ​​residue is substituted with a serine or valine residue.

[0068] Preferably, the adhesin domain comprises or consists of the sequence shown in SEQ ID NO: 33 or SEQ ID NO: 59 or SEQ ID NO: 61, or a sequence at least 80% identical thereto, wherein one or more cysteine ​​residues are substituted with serine or valine residues.

[0069] In a particularly preferred embodiment of the second aspect of the present invention, there is provided a chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis, the protein comprising a first polypeptide and a second polypeptide, wherein:

[0070] A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and

[0071] B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis;

[0072] wherein said second polypeptide comprises the sequence of one or more adhesin binding motifs (ABMs), preferably wherein said ABMs correspond to some or all of said ABMs between the DUF2436 domain and the cleaved adhesin domain (CAD) of Porphyromonas gingivalis gingipain,

[0073] Preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (ABM2), SEQ ID NO: 14 or 19 (ABM1) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0074] More preferably wherein the one or more ABMs comprise the sequence shown in any one of SEQ ID NO: 16 or SEQ ID NO: 18 or 22 or SEQ ID NO: 27, 63 or 64, or a sequence at least 80% identical thereto;

[0075] And among them

[0076] a) the second polypeptide comprises one or more cysteine ​​to serine amino acid substitutions compared to a naturally occurring adhesin domain sequence; and

[0077] b) the second polypeptide comprises a proline substitution and / or an asparagine substitution in sequence PxxN corresponding to the residues at positions 6 to 9 of the sequence of SEQ ID NO: 14 or 19 (ABM1) (corresponding to the residues at positions 63 to 66 of the sequence of SEQ ID NO: 18 or 22) or at positions equivalent to said residues.

[0078] Preferably, the chimeric or fusion protein comprises one or more additional polypeptides, the one or more additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto. The one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis may be located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide, the C-terminus of the second polypeptide.

[0079] In a preferred embodiment, the second polypeptide comprises the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis, wherein the adhesin domain comprises the sequence shown in SEQ ID NO: 18 or 22 or a sequence at least 80% identical thereto; and wherein one or two cysteine ​​residues in SEQ ID NO: 18 or 22 are substituted with serine residues, and wherein the proline and / or asparagine residues in the sequence PxxN at positions 63 to 66 of SEQ ID NO: 18 or 22 or positions equivalent thereto are substituted. Optionally, the proline residue is substituted with an alanine residue and / or the asparagine residue is substituted with a proline or alanine residue, preferably wherein the proline is substituted with an alanine and the asparagine is substituted with a proline, such that the sequence at positions 63 to 66 of SEQ ID NO: 18 or 22 is AxxP (e.g. AVQP).

[0080] In a particularly preferred embodiment, the second polypeptide comprises the amino acid sequence shown in SEQ ID NO:33 or a sequence at least 80% identical thereto, wherein one, two or three cysteine ​​residues are substituted with serine residues. Preferably, the cysteine ​​residue at residue 115 of SEQ ID NO:33 or a position equivalent thereto is not substituted with a serine or valine residue. Preferably, the cysteine ​​residue at position 115 of SEQ ID NO:33 or a position equivalent thereto is not substituted with a serine or valine residue, and the cysteine ​​residues at positions 208 and 222 of SEQ ID NO:33 or a position equivalent thereto are substituted with a serine residue.

[0081] In a particularly preferred embodiment, the second polypeptide comprises the amino acid sequence shown in SEQ ID NO:33 or a sequence at least 80% identical thereto, wherein one, two or three cysteine ​​residues are substituted with serine residues, and wherein the proline residues and the asparagine residues at positions 235 to 238 or positions equivalent thereto in the sequence PxxN are substituted. Preferably, the cysteine ​​residue at residue 115 or a position equivalent thereto of SEQ ID NO:33 is not substituted with a serine or valine residue. Preferably, the cysteine ​​residue at position 115 or a position equivalent thereto of SEQ ID NO:33 is not substituted with a serine or valine residue, while the cysteine ​​residues at positions 208 and 222 or positions equivalent thereto of SEQ ID NO:33 are substituted with serine residues, and wherein the proline residue at position 235 or a position equivalent thereto is substituted with an alanine residue, and the asparagine residue at position 238 or a position equivalent thereto is substituted with a proline.

[0082] In a particularly preferred embodiment, the second polypeptide comprises or consists of a sequence as shown in any one of SEQ ID NOs: 34 to 48, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0083] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0084] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0085] In any embodiment, the amino acid sequence comprising the active site of the Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or consisting of the first polypeptide and the other polypeptide comprise or consist of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences, or wherein the amino acid sequences are identical. The first polypeptide and the other polypeptide can be derived from the active site of a heterologous gingipain (e.g., gingipains from different strains of Porphyromonas gingivalis). The first polypeptide and the additional polypeptide may have amino acid sequences derived from different gingipains (e.g., wherein one of the polypeptides has an amino acid sequence from the active site of Kgp and the other has an amino acid sequence from the active site of Rgp; or alternatively, wherein one of the polypeptides has an amino acid sequence from the active site of RgpA and the other has an amino acid sequence from the active site of RgpB).

[0086] In a preferred embodiment of the second aspect of the invention, the chimeric or fusion protein comprises or consists of an amino acid sequence as shown in any one of SEQ ID NO:49, 50 or 51, or a sequence that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0087] In a third aspect of the present invention, the present invention provides a chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis, the protein comprising a first polypeptide and a second polypeptide, wherein:

[0088] A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and

[0089] B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis;

[0090] wherein said second polypeptide comprises a sequence of one or more adhesin binding motifs (ABMs), preferably wherein said ABMs correspond to some or all of said ABMs between the DUF2436 domain and the cleaved adhesin domain (CAD) of Porphyromonas gingivalis gingipain;

[0091] Preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (AMB2) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0092] More preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20 (ABM2), SEQ ID NO: 14 or 19 (ABM1) and / or SEQ ID NO: 17 or 21 (ABM3) or a sequence at least 80% identical thereto,

[0093] Most preferably wherein the one or more ABMs comprise the sequence shown in any one of SEQ ID NO: 16 or SEQ ID NO: 18 or 22, or a sequence at least 80% identical thereto; and

[0094] wherein the second polypeptide comprises part or all of the sequence of a cleaved adhesin domain (CAD), preferably part or all of the sequence of a CAD having the amino acid sequence shown in SEQ ID NO: 12 or 13 or a sequence at least 80% identical thereto,

[0095] And among them:

[0096] a) the second polypeptide comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain, preferably as shown in SEQ ID NO: 23, or a sequence at least 80% identical thereto; and

[0097] The second polypeptide comprises one or more amino acid substitutions selected from the group consisting of:

[0098] b) one or more cysteine ​​amino acid substitutions in the adhesin domain compared to the naturally occurring Arg-gingipain or Lys-gingipain sequence in the corresponding region; and

[0099] c) one or more amino acid motif substitutions selected from the group consisting of:

[0100] i) substitution of proline and / or asparagine residues in the sequence PxxN corresponding to residues 6 to 9 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at positions equivalent to said residues;

[0101] ii) a substitution of the motif NxFA to SxYQ in the sequence corresponding to residues 2 to 5 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at a position equivalent to said residues;

[0102] iii) the substitution of a second tyrosine residue corresponding to, or equivalent to, the residue at position 5 of SEQ ID NO: 15 or 20 (ABM2) and a tryptophan residue corresponding to, or equivalent to, the residue at position 23 of SEQ ID NO: 14 or 19 (ABM1) into an alanine residue.

[0103] The one or more cysteine ​​amino acid substitutions may be substitutions of a serine residue or a valine residue.Preferably, the one or more cysteine ​​substitutions may include one or more substitutions of a serine residue.

[0104] In certain embodiments, only one cysteine ​​residue is substituted. In other embodiments, two or three cysteine ​​residues are substituted. In particularly preferred embodiments, the cysteine ​​residue is substituted with a combination of valine and serine residues. In other embodiments, all substituted cysteine ​​residues are substituted with serine or all substituted cysteine ​​residues are substituted with valine.

[0105] In a particularly preferred embodiment, the adhesin domain comprises a DUF2436 domain, and the cysteine ​​residue in the DUF2436 domain is substituted with serine or valine, preferably serine. In other embodiments, the adhesin domain comprises a DUF2436 domain, and the cysteine ​​residue in the DUF2436 domain is not substituted, and preferably, one or more cysteine ​​residues in the rest of the adhesin domain are substituted.

[0106] Preferably, the adhesin domain comprises or consists of the sequence shown in SEQ ID NO: 33 or SEQ ID NO: 59 or SEQ ID NO: 61, or a sequence at least 80% identical thereto, wherein one or more cysteine ​​residues are substituted with serine or valine residues.

[0107] According to this aspect of the invention, the sequence PxxN corresponding to or located at positions equivalent to residues 235 to 238 of SEQ ID NO: 33 comprises a substitution of said proline residue and said asparagine residue. Preferably, said substitution is from PxxN to AxxP.

[0108] In a particularly preferred embodiment of this aspect of the invention, the second polypeptide comprises the amino acid sequence shown in SEQ ID NO:33 or a sequence at least 80% identical thereto, wherein one, two or three cysteine ​​residues are substituted with serine residues. Preferably, the cysteine ​​residue at residue 115 of SEQ ID NO:33 or a position equivalent thereto is not substituted with a serine or valine residue. Preferably, the cysteine ​​residue at position 115 of SEQ ID NO:33 or a position equivalent thereto is not substituted with a serine or valine residue, and the cysteine ​​residues at positions 208 and 222 of SEQ ID NO:33 or a position equivalent thereto are substituted with a serine residue.

[0109] In a particularly preferred embodiment, the second polypeptide comprises the amino acid sequence shown in SEQ ID NO:33 or a sequence at least 80% identical thereto, wherein one, two or three cysteine ​​residues are substituted with serine residues, and wherein the proline residues and the asparagine residues at positions 235 to 238 or positions equivalent thereto in the sequence PxxN are substituted. Preferably, the cysteine ​​residue at residue 115 or a position equivalent thereto of SEQ ID NO:33 is not substituted with a serine or valine residue. Preferably, the cysteine ​​residue at position 115 or a position equivalent thereto of SEQ ID NO:33 is not substituted with a serine or valine residue, while the cysteine ​​residues at positions 208 and 222 or positions equivalent thereto of SEQ ID NO:33 are substituted with serine residues, and wherein the proline residue at position 235 or a position equivalent thereto is substituted with an alanine residue, and the asparagine residue at position 238 or a position equivalent thereto is substituted with a proline.

[0110] In a particularly preferred embodiment, the second polypeptide comprises or consists of a sequence as shown in any one of SEQ ID NOs: 34 to 48, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0111] In particularly preferred embodiments, the chimeric or fusion protein comprises or consists of a sequence as shown in any one of SEQ ID NO:52 or 53, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0112] Preferably, the chimerism of the fusion protein comprises one or more additional polypeptides, wherein the one or more additional polypeptides comprise or consist of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto. The one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis can be located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide, the C-terminus of the second polypeptide.

[0113] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0114] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0115] In any embodiment, the amino acid sequence comprising the active site of the Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or consisting of the first polypeptide and the other polypeptide comprise or consist of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences, or wherein the amino acid sequences are identical. The first polypeptide and the other polypeptide can be derived from the active site of a heterologous gingipain (e.g., gingipains from different strains of Porphyromonas gingivalis). The first polypeptide and the additional polypeptide may have amino acid sequences derived from different gingipains (e.g., wherein one of the polypeptides has an amino acid sequence from the active site of Kgp and the other has an amino acid sequence from the active site of Rgp; or alternatively, wherein one of the polypeptides has an amino acid sequence from the active site of RgpA and the other has an amino acid sequence from the active site of RgpB).

[0116] In any embodiment of any aspect of the invention, the chimeric or fusion protein is composed of or substantially composed of the sequence of the first polypeptide and the second polypeptide as defined herein. It should therefore be understood that the chimeric or fusion protein includes an arrangement or configuration of domains that are different from the configurations of those domains in the naturally occurring gingipain multiprotein sequence. In other words, the first polypeptide and the second polypeptide and the domain therein have a spatial configuration different from that of the naturally occurring gingipain multiprotein.

[0117] In any embodiment of any aspect of the invention, the first polypeptide and the second polypeptide are connected. The first polypeptide and the second polypeptide can be connected directly, through a linker or through a polypeptide sequence of no more than 100, preferably no more than 50 amino acids. Preferably, the first polypeptide and the second polypeptide are directly connected, or connected through no more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids. Most preferably, the first polypeptide and the second polypeptide are directly connected.

[0118] In any embodiment of any aspect of the invention, the C-terminal residue of the first polypeptide can be directly, through a linker or through a polypeptide sequence of no more than 50 amino acids, connected to the N-terminal residue of the second polypeptide. Alternatively, the N-terminal residue of the first polypeptide can be directly, through a linker or through a polypeptide sequence of no more than 50 amino acids, connected to the C-terminal residue of the second polypeptide.

[0119] According to the first to third aspects of the present invention, the DUF2436 domain and the ABM domain derived from Arg-gingipain or Lys-gingipain can be directly joined or joined through a linker or through a polypeptide sequence. Preferably, the DUF2436 domain and the ABM domain are connected by a short linker sequence comprising about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids. In a particularly preferred embodiment, the DUF domain and the ABM domain are connected by a short linker sequence of no more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids.

[0120] In a preferred embodiment, the DUF2436 domain and the ABM domain (having the representative amino acid sequences of SEQ ID NOs: 23 and 18, respectively (ie, the amino acid sequences without the amino acid substitutions described herein)) can be linked by a peptide sequence having the amino acid sequence EVEDDSP.

[0121] In any embodiment, the additional polypeptide can be joined to the chimeric or fusion protein comprising the first polypeptide and the second polypeptide directly or through a linker. In embodiments where the additional polypeptide is joined to the C-terminal region of the fusion protein via the second polypeptide, preferably the C-terminus of the second polypeptide is directly joined to the N-terminus of the additional polypeptide. (For example, the C-terminus of the adhesin domain is preferably directly joined to the N-terminus of the active site amino acid sequence).

[0122] Where more than one additional polypeptide is included, the copies of the additional polypeptides may be joined directly to each other or via a linker sequence.

[0123] In any embodiment of any aspect of the present invention, the joint region is no more than 15 amino acids, and preferably more than 2 amino acids of amino acid sequence. Suitable joints for protein constructs known in the art include joints with minimal effect on solubility. Useful joints include glycine-serine (GlySer) joints, which are well known in the art, and include glycine and serine units combined in various orders. Examples include but are not limited to (GS), (GSGGS)n, (GGGS)n and (GGGGS)n, wherein n is an integer at least one, typically an integer between 1 and about 10, such as between 1 and about 8, between 1 and about 6 or between 1 and about 5. Other useful joints include DSSG, DSSGAS, KLDSSG or other joints described herein. In certain embodiments, the joint region can be derived from a natural gingipain polyprotein sequence.

[0124] The invention also provides a nucleic acid encoding a chimeric or fusion protein as defined herein.

[0125] Preferably, the nucleic acid has a nucleotide sequence encoding any one or more of the amino acid sequences defined in Table 1 herein.

[0126] In any embodiment, such nucleic acid is contained in an expression construct, wherein the nucleic acid is operably linked to a promoter.Such expression constructs can be present in a vector (e.g., a plasmid) or a viral vector.

[0127] The present invention also provides a cell comprising a nucleic acid or a nucleic acid vector as described herein. Examples of cells of the present invention include bacterial cells, yeast cells, insect cells or mammalian cells. Preferably, the cell is isolated, substantially purified or recombinant.

[0128] The present invention also provides a composition comprising a chimeric or fusion protein as described herein, optionally in combination with a pharmaceutically acceptable carrier.

[0129] The composition may also include an adjuvant for enhancing the immune response to the chimeric or fusion protein.

[0130] Therefore, the present invention further provides a vaccine or immunostimulatory composition for inducing an immune response to Porphyromonas gingivalis in a subject, the composition comprising:

[0131] i) an immunogen in the form of a chimeric or fusion protein as described herein, and

[0132] ii) an adjuvant for enhancing the subject's immune response to the immunogen.

[0133] Preferably, the only immunogen provided in the composition, vaccine or immunostimulatory composition of the invention is a chimeric or fusion protein as described herein.

[0134] The present invention also provides a method for inducing an immune response to Porphyromonas gingivalis in a subject, the method comprising administering to a subject in need thereof a chimeric or fusion protein, vaccine or immunostimulatory composition as described herein.

[0135] The present invention also provides a method of inducing a humoral immune response to Porphyromonas gingivalis in a subject, the method comprising administering to the subject a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein.

[0136] Preferably, the induced immune response comprises a switch from a Th1 to a Th2 immune response.

[0137] It should be understood that in any embodiment, the immune response elicited by administering the chimeric or fusion protein or vaccine described herein or other compositions comprising the chimeric or fusion protein is preferably antigen-specific. Therefore, in preferred embodiments, the methods and compositions described herein and the chimeric protein are used to induce an immune response, preferably a protective immune response, to a Porphyromonas gingivalis gingipain antigen.

[0138] In any embodiment, the compositions, chimeric proteins, and methods of the invention can be used to enhance an immune response (eg, a protective immune response) to Porphyromonas gingivalis in a subject.

[0139] The present invention also provides a method of immunizing a subject against infection by Porphyromonas gingivalis, the method comprising administering to the subject a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein.

[0140] In any embodiment, a subject who has received or has been administered a chimeric or fusion protein of the invention, or a composition or vaccine comprising the chimeric or fusion protein, has an increased level of protection against Porphyromonas gingivalis infection or the severity of one or more symptoms of Porphyromonas gingivalis infection compared to a subject who has not received the protein, composition, or vaccine.

[0141] Still further, the present invention provides a method for treating a Porphyromonas gingivalis infection in a subject, the method comprising administering to a subject in need thereof a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein, thereby treating the Porphyromonas gingivalis infection in the subject.

[0142] The present invention provides a method for reducing the severity of or minimizing symptoms associated with Porphyromonas gingivalis infection, the method comprising administering to an individual in need thereof a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein, wherein the symptoms are selected from the group consisting of swollen or edematous gums, gums that bleed easily, receding gums, periodontal pockets around the teeth, loss of tissue supporting the teeth (periodontal ligament, cementum and / or alveolar bone), pus between the gums and teeth, and gingivitis.

[0143] The present invention also provides a method for treating a Porphyromonas gingivalis-associated disease in a subject, the method comprising administering a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein to an individual in need thereof. Preferably, the Porphyromonas gingivalis-associated disease comprises periodontal disease.

[0144] The present invention provides a therapeutic method, which comprises administering the chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention, and may further comprise administering one or more of the following: an antimicrobial compound, an anti-inflammatory agent.

[0145] The present invention also provides the use of a chimeric or fusion protein as defined herein for the preparation of a medicament for:

[0146] ● inducing an immune response (preferably a protective immune response) against Porphyromonas gingivalis in a subject;

[0147] ●Immunize subjects against Porphyromonas gingivalis infection;

[0148] ● Treating a subject for Porphyromonas gingivalis infection;

[0149] ● minimizing or reducing the severity of one or more symptoms of Porphyromonas gingivalis infection; or

[0150] ●Treat the subject for a Porphyromonas gingivalis-associated disease.

[0151] The present invention also provides a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein for use in:

[0152] ● inducing an immune response (preferably a protective immune response) against Porphyromonas gingivalis in a subject;

[0153] ●Immunize subjects against Porphyromonas gingivalis infection;

[0154] ● treating the Porphyromonas gingivalis infection in a subject;

[0155] ● minimizing or reducing the severity of one or more symptoms of Porphyromonas gingivalis infection; or

[0156] ●Treat the subject for a Porphyromonas gingivalis-associated disease.

[0157] In any method, use or protein, composition or vaccine for use according to the invention, the subject may be any subject already infected with or at risk of being infected with Porphyromonas gingivalis. The subject may be a human. The subject may be a veterinary subject, such as a companion animal having a Porphyromonas gingivalis infection or at risk of being infected with Porphyromonas gingivalis.

[0158] The present invention also provides a method for obtaining antibodies against Porphyromonas gingivalis, the method comprising administering the chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal. Preferably, the method further comprises isolating antibodies from the animal (e.g., extracted from the blood of the animal) or from its eggs (preferably chickens when the animal is an avian species).

[0159] The present invention also provides an antibody preparation comprising antibodies against Porphyromonas gingivalis, wherein the antibody preparation is obtained by administering the chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal, and isolating the antibodies from the animal or its eggs.

[0160] Antibodies against P. gingivalis can be used therapeutically to eliminate or reduce P. gingivalis infection, or prophylactically to prevent or reduce the severity of P. gingivalis infection.

[0161] The invention also provides a kit comprising a composition comprising a chimeric or fusion protein as defined herein, wherein optionally the kit comprises one or more cytokines and / or adjuvants in a sealed container.

[0162] Preferably, the kit comprises a label or package insert indicating that the composition is for immunizing an individual, optionally wherein the label or package insert comprises instructions for use.

[0163] Throughout this specification, unless the context otherwise requires, the words "comprise / comprises / comprising" should be understood to imply the inclusion of the stated steps or elements or a group of steps or elements, but not to exclude any other steps or elements or a group of steps or elements. Thus, the use of the terms "comprising" and the like indicates that the listed elements are required or mandatory, but other elements are optional and may or may not be present. "Consisting of" means including and limited to whatever follows the phrase "consisting of". Thus, the phrase "consisting of" indicates that the listed elements are required or mandatory, and other elements may not be present. "Substantially consisting of" means including any elements listed after the phrase, and is limited to other elements that do not interfere with or promote the activities or behaviors specified for the listed elements in the present disclosure. Thus, the phrase "consisting essentially of indicates that the listed elements are essential or mandatory, but other elements (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more additional amino acid residues at the N-terminus or C-terminus of the polypeptide sequence) are optional and may or may not be present, depending on whether they affect the activity or action of the listed elements.

[0164] Further aspects of the invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, which is given by way of example and with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0165] Figure 1 A. Mouse periodontitis model - therapeutic vaccination. B. Schematic diagram showing the domain structure of the Kgp gingipain multiprotein and components derived therefrom used to generate the chimeric or fusion proteins of the invention.

[0166] Figure 2 .SDS-PAGE of E. coli fractions expressing recombinant variants containing full-length or truncated DUF domains. Low temperature and low IPTG conditions were used. Full-length DUF is important for solubility.

[0167] Figure 3.Elimination of multimerization A. Schematic representation of the Kgp polyprotein showing the location of the ABM1 domain and the ABM2 domain. BD. Native_PAGE analysis of purified recombinant protein variants subjected to electrophoresis in the presence or absence of DTT. B: Study of "PVQN" mutant variants. C: Study of "PVQN" mutant variants with additional Cys>Ser mutations. D: Study of mutations in the "PVQN" motif pre-loop (lanes 2-4) and highly conserved hydrophobic Tyr and Trp residues (lanes 5-7) in ABM2 and ABM1, respectively. E. Native PAGE analysis of purified chimeric KDcAK1n and recombinant ABM21 with cysteine ​​and PVQP mutations. KDcAK1n was purified from inclusion bodies and recombinant ABM21 was purified as soluble protein from an E. coli expressing strain. F. Native PAGE analysis of small-scale purified recombinant variants.

[0168] Figure 4 . Bone loss study. Statistical analysis – One-way ANOVA and post hoc Dunnet's T3. #Significantly different from control challenge group.

[0169] Figure 5 . Statistical analysis of bone loss study – One-way ANOVA and post hoc Dunnett’s T3. #p<0.01; ##p<0.05 (T test) Significantly different from control challenge group.

[0170] Figure 6 . Bone loss study. S = soluble fraction; Urea = urea used for purification; AC = affinity column purification; IB = inclusion bodies; Batch = batch purification method. Statistical analysis: One-way ANOVA and post hoc Dunnett's T3. #p<0.01 significantly different from control challenge group.

[0171] Figure 7 Bone loss studies were performed after immunization of animals with various fusion protein constructs. Statistical analysis: One-way ANOVA and post hoc Dunnett's T3, significant differences from control challenge group, #p<0.05##p<0.01###p<0.001####p<0.0001.

[0172] Sequence information

[0173] Table 1: Sequence information

[0174]

[0175]

[0176]

[0177]

[0178]

[0179]

[0180] DETAILED DESCRIPTION

[0181] It should be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the various features mentioned or evident in the text or drawings. All these different combinations constitute various alternative aspects of the invention.

[0182] Reference will now be made in detail to certain embodiments of the present invention. Although the present invention will be described in conjunction with the embodiments, it will be appreciated that it is not intended to limit the present invention to those embodiments. On the contrary, the present invention is intended to encompass all alternatives, modifications and equivalents which may be included within the scope of the present invention as defined in the claims.

[0183] Those skilled in the art will recognize that many methods and materials similar or equivalent to the methods or materials described herein can be used to practice the present invention. The present invention is in no way limited to the methods and materials described. It should be understood that the present invention disclosed and defined in this specification extends to all alternative combinations of two or more features in each feature mentioned or evident in the text or drawings. All of these different combinations constitute various alternative aspects of the present invention.

[0184] All patents and publications mentioned herein are incorporated by reference in their entirety.

[0185] For the purpose of interpreting this specification, terms used in the singular will also include the plural form, and vice versa.

[0186] In the work leading to the present invention, the inventors investigated various chimeric or fusion proteins for inducing an immune response to P. gingivalis, as well as methods for large-scale production of such chimeras for use as vaccine candidates.

[0187] The present inventors have identified various problems associated with large-scale preparation and production of chimeric or fusion proteins of components derived from Porphyromonas gingivalis gingivalin. First, the chimeric or fusion proteins described in the prior art are difficult to produce in sufficiently high quantities as soluble proteins. More specifically, the chimeric proteins of the prior art are typically produced in inclusion bodies in Escherichia coli, which makes it challenging to produce large amounts of soluble proteins for downstream clinical product development.

[0188] The reduced solubility when produced in E. coli also greatly increases the time and scale of preparation, and the protein suffers from poor stability once solubilized and refolded from inclusion bodies.

[0189] Still further, the gingipain-derived chimeric proteins described in the prior art also suffer from multimerization. From a regulatory perspective, the formation of beta sheets between domains in chimeric proteins makes the evaluation of the final vaccine product challenging and may reduce the immune response once administered.

[0190] Thus, the present invention relates to improved designs of chimeric or fusion proteins for inducing an immune response to Porphyromonas gingivalis, as well as methods and uses comprising said improved designs.

[0191] In any embodiment, the chimeric or fusion protein of the present invention has improved solubility and / or stability compared to the chimeric or fusion protein described in the prior art. When it comes to large-scale production of fusion proteins for clinical settings, improved solubility and / or stability provide significant advantages.

[0192] In alternative embodiments, the chimeric or fusion proteins of the present invention have a reduced tendency to aggregate and multimerize compared to prior art chimeric or fusion proteins. Aggregation and multimerization may hinder large-scale preparation and production of therapeutic / prophylactic proteins. Therefore, reducing the aggregation and / or multimerization tendency of the chimeric proteins of the present invention provides a significant improvement over prior art chimeric proteins for inducing an immune response to Porphyromonas gingivalis.

[0193] Still further, in any embodiment, the chimeric or fusion protein of the present invention has increased immunogenicity compared to the chimeric or fusion proteins of the prior art.

[0194] Thus, the present inventors have identified various novel methods for obtaining chimeric or fusion proteins for inducing an immune response to Porphyromonas gingivalis and which have resulted in chimeric or fusion proteins having one or more advantages over the prior art.

[0195] The inventors believe that one or more of the novel methods for producing chimeric or fusion proteins to induce an immune response to Porphyromonas gingivalis, as described herein, may provide advantages including: easier preparation of suitable immunogenic compositions for inducing an immune response to Porphyromonas gingivalis; extended shelf life and / or improved immunogenicity.

[0196] Gingipain

[0197] The pathogenicity of P. gingivalis is attributed to many surface-associated virulence factors, including cysteine ​​proteases (gingipains), pili, heme-binding proteins, and outer membrane transporters. Specifically, the extracellular Arg-specific and Lys-specific proteases 'gingipains' (RgpA / B and Kgp) of P. gingivalis are considered to be major virulence factors that are essential for colonization, penetration into host tissues, dysregulation of immune responses, dysbiosis, and disease.

[0198] Gingival proteases, especially the Lys-specific protease Kgp, are essential for P. gingivalis to induce alveolar bone resorption in a mouse model of periodontitis. In gingival tissue at sites of severe periodontitis, high concentrations of gingival proteases near subgingival plaques and low concentrations at distal sites deep in the gingival tissue have also been found. Lys-specific and Arg-specific proteases have been shown to degrade a variety of host proteins in vitro, for example, fibrinogen, fibronectin, and laminin. Plasma host defense and regulatory protease inhibitors α-trypsin, α2-macroglobulin, antichymotrypsin, antithrombin III, and antiplasmin are also degraded by Lys- and Arg-proteases of P. gingivalis. This has led to the development of a convincing mechanism to explain the key role played by P. gingivalis in the development of chronic periodontitis.

[0199] The RgpA, RgpB and Kgp genes all encode an N-terminal signal peptide of about 22 amino acids in length, an abnormally long propeptide of about 200 amino acids in length and a catalytic domain of about 480 amino acids in length. The C-terminus of the catalytic domain is a large hemagglutinin-adhesin (HA) domain, which contains an adhesin binding domain (ABM, or 5 different sequences that have been described), a "domain of unknown function" (called DUF2436, defined as a conserved Pfam domain of unknown function; IPR018832) and a C-terminal adhesin domain or a cleaved adhesin domain (or CAD). The specific arrangement of ABM, DUF and CAD differs between Kgp and RgpA / B.

[0200] The domain architecture of the Kgp polyprotein is Figure 1 B. For example, Kgp includes (N-terminal to C-terminal): a catalytic domain, a first ABM (ABM1), DUF2436, a domain including ABM2, ABM1, ABM3, two CAD domains (referred to as K1 and K2), an additional domain including ABM1 and ABM2, an additional CAD domain (referred to as K3), ABM2, and a C-terminal domain.

[0201] As used herein, references to ABMs 1, 2, and 3 will be understood to generally refer to the ABMs found in the order ABM2, ABM1, and ABM3 in the sequence immediately following the C-terminus of DUF2436 of Kgp, e.g. Figure 1 Depicted by B.

[0202] The catalytic domains of RgpB and RgpA share a high degree of sequence homology. However, RgpB lacks the HA domain and is located on the outer membrane as a monomer. Some of the HA domains have been alternatively described as C-terminal adhesin domains or cleaved adhesin domains (CAD), and some are DUF ("domain of unknown function") 2436 domains (conserved Pfam domain of unknown function; IPR018832).

[0203] RgpA and Kgp precursor proteins are cut into multiple domains, and the multiple domains keep non-covalent association to form a large outer membrane protein complex. Therefore, in vivo, Arg-specific proteases and Lys-specific proteases are found in the complex of non-covalently associated proteases and cell association of adhesins. A kind of such complex is named as RgpA-Kgp protease-adhesin complex (previously known as PrtR-PrtK protease-adhesin complex). The complex is composed of a cysteine ​​protease stable by 45kDa Arg specific calcium and seven sequence-related adhesin domains.

[0204] As used herein, Lys-gingipain catalytic domain may also be referred to as KAS domain or PAS domain. As used herein, Arg-gingipain catalytic domain may also be referred to as RAS domain or PAS domain. Typically, the catalytic domain of Lys-gingipain or Arg-gingipain is located in the region of approximately 480 amino acids at the N-terminal of the protein. The active site in the catalytic domain is typically located at amino acid residues 426-446 (for RgpA) and 432-453 (for Kgp). Table 1 lists exemplary active site peptides found in the catalytic domain, such as SEQ ID NO: 1-11.

[0205] As used herein, the adhesin domain of the Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis will be understood to refer generally to the region of the Arg-gingipain or Lys-gingipain located at the C-terminus of the catalytic or active site domain. The adhesin domain (also referred to as the HA domain) generally includes a domain of unknown function (DUF) domain (particularly the conserved Pfam domain of unknown function of DUF 2436; IPR018832) and several adhesin binding motif (ABM) domains and a cleaved adhesin domain (CAD).

[0206] First polypeptide

[0207] The chimeric or fusion protein of the present invention comprises a first polypeptide comprising or consisting of an amino acid sequence of the active site of Arg-X protease or Lys-X protease (also referred to herein as Arg-gingipain or Lys-gingipain, respectively) of Porphyromonas gingivalis or a sequence at least 80% identical thereto.

[0208] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0209] Improved immunogenicity

[0210] Preferably, the chimeric or fusion protein comprises one or more additional polypeptides, the one or more additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto. The one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis may be located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide or the C-terminus of the second polypeptide. The one or more additional polypeptides may be connected to the first polypeptide or the second polypeptide of the chimeric or fusion protein, preferably through a linker of no more than 50 amino acids, or directly connected to the first polypeptide.

[0211] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0212] In any embodiment, the first polypeptide and the additional polypeptide comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis comprise or consist of the same amino acid sequence or sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each other.

[0213] In a preferred embodiment, the chimeric or fusion protein of the present invention comprises no more than 2 or no more than 3 or no more than 4 polypeptides, the polypeptides comprising the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto or consisting thereof. Preferably, the chimeric or fusion protein of the present invention has less than 5, more preferably less than 4, most preferably less than 3 polypeptides, the polypeptides comprising the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto or consisting thereof.

[0214] The second polypeptide

[0215] The chimeric or fusion protein of the present invention comprises a second polypeptide comprising or consisting of the amino acid sequence of the adhesin domain of the ArgX protease or Lys-X protease of Porphyromonas gingivalis or a sequence at least 80% identical thereto.

[0216] It will be appreciated that the second polypeptide will typically include at least one sequence corresponding to one or more of the adhesin binding motifs (ABMs), which are recognized domains / motifs in the adhesin domains of the ArgX protease or Lys-X protease (e.g., Kgp and RgpA) of Porphyromonas gingivalis.

[0217] Five ABMs (ABM1-5) have been defined for Kgp and RgpA. Exemplary sequences of these ABMs are shown in Table 1.

[0218] Typically, the second polypeptide includes more than one ABM, preferably, wherein the second polypeptide includes at least ABM1 and ABM2, or a sequence at least 80% identical to each of ABM1 or ABM2. The second polypeptide may also include the sequence of ABM3 or a sequence at least 80% identical thereto.

[0219] It is also understood that the arrangement of the ABM peptides in the second polypeptide need not correspond to the arrangement of the ABM peptides found in a naturally occurring adhesin domain. For example, the ABM peptides may be arranged in the second polypeptide in the sequence (N-terminal to C-terminal) ABM1, ABM2, ABM3, etc. Alternatively, the ABM peptides may be arranged to reflect the arrangement in a naturally occurring adhesin domain (such as ABM2, ABM1, and ABM3), such as that present in adhesin domain 1 of Kgp.

[0220] Still further, the ABMs in the second polypeptide may be arranged consecutively, or may be separated from each other by an amino acid sequence of no more than 50 amino acids. It will be appreciated by those skilled in the art that the spacing between ABMs is not important in the design of the chimeric or fusion proteins of the present invention.

[0221] In any embodiment, the second polypeptide comprises an amino acid sequence as shown in SEQ ID NO:62, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0222] In any embodiment, the second polypeptide comprises an amino acid sequence as shown in SEQ ID NO:16, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0223] In any embodiment, the second polypeptide comprises an amino acid sequence as shown in SEQ ID NO:18, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0224] In any embodiment, the second polypeptide comprises an amino acid sequence as shown in SEQ ID NO:22, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0225] In any embodiment, the second polypeptide comprises an amino acid sequence as shown in SEQ ID NO:27, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0226] However, the present inventors have found that when the chimeric or fusion protein of the present invention includes only a portion of the DUF2436 domain (ie, an N-terminally truncated DUF2436 domain, as shown in SEQ ID NOs: 25 and 27), the solubility of the chimeric or fusion protein of the present invention is reduced.

[0227] With reference to the examples of this specification, the inventors have recognized that prior art methods for designing Porphyromonas gingivalis vaccines include N-terminal truncated forms of the DUF2436 domain. Although the truncated DUF2436 domain represents how the Kgp polyprotein is proteolytically processed and assembled on the cell surface, the inventors have found that providing a full-length sequence of the DUF2436 domain (i.e., including the N-terminal portion of the DUF2436 domain) greatly improves the production of soluble recombinant protein.

[0228] Thus, in a preferred embodiment, the second polypeptide in the chimeric or fusion protein of the invention comprises residues 1 to 37 of the DUF2436 domain, preferably wherein the chimeric protein comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain, or a sequence that is at least 80% identical thereto.

[0229] As used herein, an amino acid sequence substantially corresponding to the full length of a DUF2436 domain, or a sequence that is at least 80% identical thereto, refers to a sequence that accounts for at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the length of the DUF2436 domain of Arg-gingipain or Lys-gingipain.

[0230] Preferably, the DUF2436 domain comprises the sequence shown in SEQ ID NO:23, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0231] Thus, in preferred embodiments, the second polypeptide comprises an amino acid sequence as shown in any one of SEQ ID NOs: 33, 59 or 61, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

[0232] The inventors have also determined that various domains in gingipains have a tendency to multimerize, which contributes to reduced solubility of chimeric or fusion proteins and reduced immunogenicity when multimerized or aggregated. Therefore, the formation of multimers has an impact on the ease of large-scale production of chimeric proteins derived from gingipain sequences and use as vaccines, but may also affect the generation of protective responses.

[0233] Specifically, the inventors have identified two mechanisms for multimer formation: the formation of disulfide bridges between cysteine ​​residues and the exchange of β-strands between ABM domains. Figure 1 Schematic diagram depicting the various domains of Kgp in B. The inventors hypothesized that ABM1 may interact with its next available neighbor ABM2 during the in vivo folding of the Kgp polyprotein. Separately, the inventors showed that co-expression of recombinant ABM1 and ABM2 as separate proteins was able to form a stable β-sheet complex structure.

[0234] Therefore, in order to reduce the multimerization of the chimeric proteins proposed according to the present invention, in addition to targeting specific motifs within ABM 2 and 1, the inventors also targeted the cysteine ​​residues of the DUF and ABM domains, which are likely responsible for beta sheet formation.

[0235] The inventors have identified that one or more of the following modifications contribute to reduced multimerization of chimeric fusion proteins derived from Kgp and Rgp polyproteins:

[0236] c) comprises one or more cysteine ​​amino acid substitutions in the amino acid sequence of the DUF 2436 domain and / or the ABM domain compared to the naturally occurring Arg-gingipain or Lys-gingipain sequence in the corresponding region; and / or preferably and

[0237] d) comprises one or more amino acid motif substitutions selected from the group consisting of:

[0238] i) substitution of proline and / or asparagine residues in the sequence PxxN corresponding to residues 6 to 9 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at positions equivalent to said residues;

[0239] ii) a substitution of the motif NxFA to SxYQ in the sequence corresponding to residues 2 to 5 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at a position equivalent to said residues;

[0240] iii) the substitution of a second tyrosine residue corresponding to, or equivalent to, the residue at position 5 of SEQ ID NO: 15 or 20 (ABM2) and a tryptophan residue corresponding to, or equivalent to, the residue at position 23 of SEQ ID NO: 14 or 19 (ABM1) into an alanine residue.

[0241] Thus, in particularly preferred embodiments of the invention, the second polypeptide comprises one or more cysteine ​​amino acid substitutions compared to a naturally occurring adhesin domain sequence.

[0242] Cysteine ​​residues are found in (at least) the DUF2436 domain of the Porphyromonas gingivalis Kgp sequence, ABM2 and K1 CAD sequences. Thus, it is to be understood that the present invention contemplates chimeric or fusion proteins in which one or more, two or more, or three or more cysteine ​​residues are substituted to reduce, minimize or eliminate the formation of disulfide bridges.

[0243] The cysteine ​​amino acid substitution may be a substitution of a serine residue or a valine residue. Preferably, the one or more cysteine ​​substitutions comprise one or more substitutions of a serine residue.

[0244] In a particularly preferred embodiment, the cysteine ​​residues in the DUF2436 domain are not substituted, while one or more cysteine ​​residues in the region of the adhesin domain between the C-terminus of the DUF2436 domain and the N-terminus of the K1 CAD domain may be substituted. An exemplary sequence of the region between the DUF domain and the CAD domain is shown in SEQ ID NO: 18 or 22. In a preferred embodiment of the present invention, one or both of the cysteine ​​residues at positions 36 and 50 or positions equivalent thereto are substituted, optionally with serine or valine residues, preferably with serine residues.

[0245] An exemplary sequence of the DUF2436 domain plus the ABM2+1+3 region is shown in SEQ ID NO: 33. An exemplary sequence of the DUF2436 domain plus the ABM2+1 region and exemplary sequences of the DUF2436 domain and ABM 2 and 3 are listed in SEQ ID NO: 59 and 61, respectively. In a preferred embodiment of the present invention, one or both of the cysteine ​​residues at positions 208 and 222 of SEQ ID NO: 33 or positions equivalent thereto are substituted, optionally with serine or valine residues, preferably with serine residues.

[0246] In alternative embodiments, the cysteine ​​residues in the DUF2436 domain are substituted with serine or valine residues, preferably serine residues, and one or two cysteine ​​residues in the region of the adhesin domain between the C-terminus of the DUF2436 domain and the N-terminus of the K1 CAD domain may be substituted. An exemplary sequence of the region between the DUF domain and the CAD domain is shown in SEQ ID NO: 18. In a preferred embodiment of the present invention, one or two cysteine ​​residues at positions 36 and 50 or positions equivalent thereto are substituted, optionally substituted with serine or valine residues, preferably substituted with serine residues. An exemplary sequence of the DUF2436 domain plus ABM2+1+3 region is shown in SEQ ID NO: 33. In a preferred embodiment of the present invention, the cysteine ​​residue at position 115 and one or two cysteine ​​residues at positions 208 and 222 or positions equivalent thereto are substituted, optionally substituted with serine or valine residues, preferably substituted with serine residues.

[0247] Therefore, in a particularly preferred embodiment, the chimeric or fusion protein of the present invention comprises an amino acid sequence corresponding to the sequence as shown in any one of SEQ ID NOs: 34 to 48 or a sequence that is at least 80% identical thereto (except for the cysteine ​​substitution therein).

[0248] The inventors have further determined that mutation of conserved motifs present in ABM domains 2, 1 and 3 also reduces multimerization.

[0249] In one example, the inventors considered modification of the domain at the N-terminus of the ABM1 of the adhesin domain. More specifically, it was found that substitution of the motif PXXN (e.g., PVQN in the ABM1 of Porphyromonas gingivalis Kgp, as shown at residues 6 to 9 in SEQ ID NO: 14 or 19) significantly helped to reduce multimerization between ABM domains and reduce β-strand exchange.

[0250] Thus, in a preferred embodiment, the chimeric or fusion protein of the invention comprises a modification of the ABM1 PXXN motif in the region of the chimeric or fusion protein corresponding to the adhesin domain of Porphyromonas gingivalis gingipain. Thus, the second polypeptide preferably comprises a proline substitution and an asparagine substitution in the sequence PxxN corresponding to positions 6 to 9 of the sequence of SEQ ID NO: 14 or 19 defining ABM1 or at positions equivalent to said positions.

[0251] The proline amino acid substitution is preferably a substitution with an alanine residue.

[0252] The asparagine amino acid substitution can be a substitution of a proline residue or an alanine residue. Preferably, the asparagine residue is substituted with a proline residue. In other embodiments, the asparagine residue is not substituted.

[0253] In another example, the inventors considered the motif NEFA in the sequence of ABM1. This sequence is defined at residues 2 to 5 of SEQ ID NOs: 14 and 19 herein. As further demonstrated in the examples, modification of the motif NEFA to SEQY significantly reduced multimerization by replacing asparagine, phenylalanine and alanine residues with serine, glutamine and tyrosine, respectively.

[0254] In another example, the inventors determined that substitution of a second tyrosine residue in ABM2 corresponding to or equivalent to the residue at position 5 of SEQ ID NO: 15 and a tryptophan residue in ABM1 corresponding to or equivalent to the residue at position 23 of SEQ ID NO: 14 or 19 into an alanine residue also significantly reduced multimerization.

[0255] Finally, the inventors discovered that multimerization was nearly eliminated by a combination of cysteine ​​modification and one or more of the following substitutions:

[0256] i) substitution of proline and / or asparagine residues in the sequence PxxN corresponding to residues 6 to 9 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at positions equivalent to said residues;

[0257] ii) a substitution of the motif NxFA to SxYQ in the sequence corresponding to residues 2 to 5 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at a position equivalent to said residues;

[0258] iii) the substitution of a second tyrosine residue corresponding to, or equivalent to, the residue at position 5 of SEQ ID NO: 15 or 20 (ABM2) and a tryptophan residue corresponding to, or equivalent to, the residue at position 23 of SEQ ID NO: 14 or 19 (ABM1) into an alanine residue.

[0259] In a particularly preferred embodiment, the inventors have found that a combination of one or more cysteine ​​modifications, preferably at least 2 cysteine ​​substitutions for serine, and modification of the PxxN motif of ABM1 to AxxP abolishes multimerization of the resulting recombinant chimeric protein.

[0260] In summary, cysteine ​​modifications and modifications of the PxxN motif of the ABM1 domain, the present invention therefore provides a chimeric or fusion protein as described herein, wherein the second polypeptide of the chimeric protein corresponding to a region of the adhesin domain of Porphyromonas gingivalis Arg gingipain or Lys gingipain comprises or consists of an amino acid sequence as shown in SEQ ID NO: 33 or a sequence at least 80% identical thereto, wherein one, two or three cysteine ​​residues are substituted with serine residues, and / or wherein the proline residue and the asparagine residue at positions 235 to 238 or positions equivalent thereto in the sequence PxxN are substituted.

[0261] Preferably, the cysteine ​​residue at residue 115 of SEQ ID NO: 33, or a position equivalent thereto, is not substituted with a serine or valine residue.

[0262] Preferably, the cysteine ​​residue at position 115 of SEQ ID NO:33 or a position equivalent thereto is not substituted with a serine or valine residue, while the cysteine ​​residues at positions 208 and 222 of SEQ ID NO:33 or positions equivalent thereto are substituted with serine residues, and wherein the proline residue at position 235 or a position equivalent thereto is substituted with an alanine residue, and the asparagine residue at position 238 or a position equivalent thereto is substituted with proline.

[0263] Linking of the first polypeptide to the second polypeptide

[0264] In the chimeric or fusion proteins of the invention, the C-terminal residue of the first polypeptide can be covalently linked to the N-terminal residue of the second polypeptide (corresponding to the adhesin domain polypeptide), or the N-terminal residue of the first peptide can be covalently linked to the C-terminal residue of the second polypeptide (corresponding to the adhesin domain polypeptide). In this arrangement, the first peptide and the adhesin domain polypeptide are referred to as "directly connected" or "adjacent".

[0265] In other embodiments, the chimeric or fusion protein comprises a linker for connecting the first peptide to the adhesin domain polypeptide.The linker can be any linker capable of joining a peptide to a polypeptide, including both amino acid linkers and non-amino acid linkers.

[0266] Preferably, the linker is non-immunogenic. Typically, the linker comprises amino acids, and may therefore be referred to as a peptide linker.

[0267] The linker is typically a peptide of up to 20 amino acids in length, although it may be longer. The term "connected to ... " or "fused to ... " refers to a covalent bond (e.g., a peptide bond) formed between two parts. Therefore, in the context of the present invention, the length of the linker can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 or more amino acids. For example, the chimeric or fusion protein provided herein can include a linker between a first polypeptide and a second polypeptide (e.g., between the N-terminus of the second polypeptide and the C-terminus of the first polypeptide), wherein the first polypeptide includes or is composed of the amino acid sequence of the active domain of Porphyromonas gingivalis gingivalis protease, and the second polypeptide corresponds to the adhesin domain of Porphyromonas gingivalis gingivalis protease. The advantage of this type of linker is that it can make it more likely that the different polypeptides of the fusion protein are independently folded and exhibit expected behavior. Suitable linkers may be up to 50 amino acids in length, although less than 20, less than 15 or less than five amino acids are preferred. The linker may serve to place the first peptide and the adhesin domain polypeptide in closer spatial arrangement than is normally observed in the Porphyromonas gingivalis trypsin-like enzyme. Alternatively, it may separate the first polypeptide from the second polypeptide (corresponding to the adhesin domain polypeptide).

[0268] Suitable joints for protein constructs known in the art include joints with minimal effect on solubility. The joint may be any joint known to those skilled in the art, and may be a flexible joint (such as a joint including a repeat sequence of glycine residues and serine residues), a rigid joint (such as a joint including glutamic acid residues and lysine residues, a joint flanking an alanine repeat sequence) and / or a cleavable joint (such as a sequence susceptible to protease cleavage). Examples of such joints are known to those skilled in the art, and are described, for example, in Chen et al., (2013) Advanced Drug Delivery Reviews, 65: 1357-1369.

[0269] Useful linkers include glycine-serine (GlySer) linkers, which are well known in the art and include glycine and serine units combined in various orders. Examples include, but are not limited to, (GS), (GSGGS)n, (GGGS)n, and (GGGGS)n, wherein n is an integer of at least one, typically an integer between 1 and about 10, such as between 1 and about 8, between 1 and about 6, or between 1 and about 5.

[0270] In some embodiments, peptide linkers can include amino acid glycine and serine of various lengths and combinations. In some aspects, peptide linkers can include sequence Gly-Gly-Ser (GGS), Gly-Gly-Gly-Ser (GGGS) or Gly-Gly-Gly-Gly-Ser (GGGGS) and variants or repetitive sequences thereof. In some aspects, peptide linkers can include amino acid sequence GGGGS (joints of 6 amino acids in length) or even longer. Linkers can be a series of repeated glycine and serine residues (GS) of different lengths, i.e. (GS) n, wherein n is any number from 1 to 15 or greater. For example, linkers can be (GS) 3 (i.e. GSGSGS) or longer (GS) 11 or longer. It should be understood that n can be any number including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or more. The fusion protein of the linker with such length is included in the scope of the present invention. Similarly, linkers can be a series of repeated glycine residues separated by serine residues. For example, (GGGGS)3 (ie, the linker may comprise the amino acid sequence GGGGSGGGGSGGGGS(G4S)3) and variants thereof.

[0271] In one embodiment, the peptide linker may comprise the amino acid sequence GGGGS (a linker of 6 amino acids in length) or even longer. The linker may be a series of repeated glycine and serine residues (GS) of varying lengths, i.e., (GS)n, wherein n is any number from 1 to 15 or greater. For example, the linker may be (GS)3 (i.e., GSGSGS) or longer (GS)11 or longer. It should be understood that n may be any number comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or more.

[0272] Other useful linkers include DSSG, DSSGAS, KLDSSG, and variants thereof. Examples of other suitable linkers are described in Chen et al., (2013) Advanced Drug Delivery Reviews, 65: 1357-1369.

[0273] Chimeric or fusion proteins and recombinant proteins

[0274] Chimeric or fusion proteins of the invention can be prepared by any of a variety of conventional techniques, although typically recombinant techniques are used to prepare the polypeptides.

[0275] In the case of a recombinant polypeptide, a DNA fragment encoding the desired peptide can be subcloned into an appropriate vector using well-known molecular genetic techniques (see, e.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory, 1982); Sambrook et al., Molecular Cloning A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory, 1989). The fragment can be transcribed and the polypeptide subsequently translated in vitro. Commercially available kits (e.g., as prepared by Clontech, Palo Alto, Calif.; Amersham Pharmacia Biotech, Piscataway, N.J.) can also be used. Inc., Piscataway, NJ); InVitrogen, Carlsbad, Calif., etc. The polymerase chain reaction can optionally be used to manipulate nucleic acids.

[0276] A "fragment" is a portion of a polypeptide of the invention that retains substantially similar functional activity or substantially the same biological function or activity as the polypeptide, as can be determined using the assays described herein.

[0277] "Percentage (%) of amino acid sequence identity" or "percentage (%) identity" with respect to polypeptide sequences (i.e., polypeptides of the invention as defined herein) is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular polypeptide of the invention, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percentage of sequence identity and without considering any conservative substitutions as part of the sequence identity. Reference herein to a variant having "at least x% sequence identity" to a sequence means that the variant is at least x% identical to the sequence.

[0278] In various aspects and embodiments of the present invention, the defined polypeptides are described by reference to variants having at least 80% homology or higher homology to a reference sequence. Percent homology (%) generally refers to the polypeptides of the invention as defined herein, and is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular polypeptide of the invention, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percentage of sequence identity and not considering any conservative substitutions as part of the sequence identity.

[0279] The amino acids glycine, alanine, valine, leucine, and isoleucine are often interchangeable (amino acids with aliphatic side chains). Of these possible substitutions, it is preferred to use glycine and alanine to replace each other (because they have relatively short side chains), and to use valine, leucine, and isoleucine to replace each other (because they have larger, hydrophobic, aliphatic side chains). Other amino acids that are often interchangeable include: phenylalanine, tyrosine, and tryptophan (amino acids with aromatic side chains); lysine, arginine, and histidine (amino acids with basic side chains); aspartic acid and glutamic acid (amino acids with acidic side chains); asparagine and glutamine (amino acids with amide side chains); and cysteine ​​and methionine (amino acids with sulfur-containing side chains).

[0280] Substitutions of this nature are often referred to as "conservative" or "semi-conservative" amino acid substitutions.

[0281] Amino acid deletions or insertions can also be made relative to the native sequence of the Porphyromonas gingivalis protein. Thus, for example, amino acids that do not substantially affect the activity of the polypeptide or at least do not eliminate such activity can be deleted. Such deletions may be advantageous, particularly for longer polypeptides, because the overall length and molecular weight of the polypeptide can be reduced while still maintaining activity. This can enable the amount of polypeptide required for a particular purpose to be reduced, for example, the dosage level can be reduced.

[0282] Amino acid insertions relative to the native polypeptide sequence may also be made. This may alter the properties of the polypeptides used in the invention (e.g. to enhance antigenicity).

[0283] Amino acid changes can be made using any suitable technique, for example by using site-directed mutagenesis or solid-state synthesis.

[0284] It will be appreciated that amino acid substitutions or insertions within the scope of the present invention may be made using naturally occurring or non-naturally occurring amino acids.Whether natural or synthetic amino acids are used, it is preferred that only L-amino acids are present.

[0285] Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm required to achieve maximum alignment over the full length of the sequences being compared (non-limiting examples described below). When amino acid sequences are aligned, the percentage of amino acid sequence identity between a given amino acid sequence A and (and, or for) a given amino acid sequence B (which can alternatively be expressed as a given amino acid sequence A having or including a certain percentage of amino acid sequence identity with (and, or for) a given amino acid sequence B) can be calculated as: percentage of amino acid sequence identity = X / Y100, where X is the number of amino acid residues scored as identical matches by the alignment of A and B by the sequence alignment program or algorithm, and Y is the total number of amino acid residues in B. If the length of amino acid sequence A is not equal to the length of amino acid sequence B, the percentage of amino acid sequence identity between A and B will not be equal to the percentage of amino acid sequence identity between B and A.

[0286] When calculating the percent identity, the exact matches are usually counted. The determination of the percent identity between two sequences can be completed using a mathematical algorithm. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, as modified in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such algorithms are incorporated into the BLASTN and BLASTX programs of Altschul et al. (1990) J. MoI. Biol. 215:403. In order to obtain a gap comparison for comparison purposes, a gapped BLAST (in BLAST 2.0) as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389 can be used. Alternatively, PSI-Blast can be used for iterative search for detecting the distance relationship between two molecules. See Altschul et al. (1997) the same. When using BLAST, BLAST and PSI-Blast programs with vacancies, the default parameters of each program (e.g., BLASTX and BLASTN) can be used. It is also possible to manually compare by inspection. Another non-limiting example of a mathematical algorithm for sequence comparison is the ClustalW algorithm (Higgins et al. (1994) Nucleic Acids Research 22:4673-4680). ClustalW compares multiple sequences and aligns all amino acids or DNA sequences, and therefore can provide data on the sequence conservation of all amino acid sequences. The ClustalW algorithm is used in several commercially available DNA / amino acid analysis software packages, such as the ALIGNX module of the Vector NTI program suite (Invitrogen Corporation, Carlsbad, CA, of Carlsbad, California). After amino acid sequence alignment with ClustalW, percentage amino acid identity can be estimated. A non-limiting example of a software program useful for analysis of ClustalW alignments is GENEDOC TM Or JalView (http: / / www.jalview.org / ). GENEDOC TMIt allows to evaluate the amino acid (or DNA) similarity and identity between multiple proteins.Another non-limiting example of a mathematical algorithm for sequence comparison is the algorithm of Myers and Miller (1988) "Computer Applications in Biological Sciences (CABIOS)" 4:11-17. Such an algorithm is incorporated into the ALIGN program (Version 2.0), which is a GCG Wisconsin Genetics Software Package, Version 10 (obtained from Accelrys, Inc., 9685 Scranton Rd., San Diego, CA, USA). When the ALIGN program is used to compare amino acid sequences, a PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

[0287] The polypeptide ideally includes an amino terminus and a carboxyl terminus. The polypeptide may include a D-amino acid, an L-amino acid, or a mixture of a D-amino acid and an L-amino acid. However, the D-type of amino acids is particularly preferred because polypeptides comprising D-amino acids are expected to have greater retention of their biological activity in vivo.

[0288] As used herein, the term "conservative substitution" refers to replacing an amino acid present in the native sequence of a peptide with a naturally or non-naturally occurring amino acid or a peptide mimetic having similar stereo characteristics. If the side chain of the natural amino acid to be replaced is polar or hydrophobic, the conservative substitution should be the use of a naturally occurring amino acid, a non-naturally occurring amino acid, or a peptide mimetic moiety that is polar or hydrophobic (in addition to having the same stereo characteristics as the side chain of the replaced amino acid).

[0289] Conservative amino acid substitution tables providing functionally similar amino acids are well known to those skilled in the art. The following six groups are examples of amino acids that can be considered conservative substitutions of each other:

[0290] 1) Alanine (A), serine (S), threonine (T);

[0291] 2) Aspartic acid (D), glutamic acid (E);

[0292] 3) Asparagine (N), glutamine (Q);

[0293] 4) Arginine (R), Lysine (K);

[0294] 5) isoleucine (I), leucine (L), methionine (M), valine (V); and

[0295] 6) Phenylalanine (F), tyrosine (Y), tryptophan (W).

[0296] Since naturally occurring amino acids are generally grouped according to their properties, conservative substitutions of naturally occurring amino acids can be determined, taking into account the fact that replacement of charged amino acids with spatially similar non-charged amino acids is considered a conservative substitution. In order to produce conservative substitutions by non-natural amino acids, amino acid analogs (synthetic amino acids) well known in the art can also be used. Naturally occurring amino acid peptide mimetics are well documented in the literature known to those skilled in the art, and non-natural (non-natural or unnatural) amino acids are further described below. When affecting conservative substitutions, the substituted amino acid should have the same or similar functional groups in the side chain as the original amino acid.

[0297] As used herein, the phrase "non-conservative substitution" or "non-conservative residue" refers to the replacement of an amino acid present in the parent sequence with another naturally occurring or non-naturally occurring amino acid having different electrochemical and / or steric properties. Thus, the side chain of the substituted amino acid may be significantly larger (or smaller) than the side chain of the substituted natural amino acid and / or may have a functional group with significantly different electronic properties from the substituted amino acid. Examples of such non-conservative substitutions include the replacement of alanine with phenylalanine or cyclohexylmethylglycine, the replacement of glycine with isoleucine, or the replacement of aspartic acid with -NH-CH[(-CH2)5-COOH]-CO-. Non-conservative substitutions include any mutation that is not considered conservative.

[0298] Non-conservative amino acid substitutions may result from changes in: (a) the structure of the amino acid backbone in the region of the substitution; (b) the charge or hydrophobicity of the amino acid; or (c) a large portion of the amino acid side chain. Substitutions that are generally expected to produce the greatest changes in protein properties are: (a) substitution of a hydrophilic residue for (or by) a hydrophobic residue; (b) substitution of proline for (or by) any other residue; (c) substitution of a residue with a large side chain (e.g., phenylalanine) for (or by) a residue with no side chain (e.g., glycine); or (d) substitution of an electronegative residue (e.g., glutamyl or aspartyl) for (or by) a residue with a positively charged side chain (e.g., lysyl, arginyl, or histidyl).

[0299] The change of the native amino acid sequence to produce a mutant polypeptide (such as by insertion, deletion and / or substitution) can be carried out in various ways known to those skilled in the art. For example, by connecting a synthetic oligonucleotide comprising a modified site to an expression vector, a site-specific mutation can be introduced. Alternatively, an oligonucleotide-directed site-specific mutagenesis program can be used, as disclosed in: Walder et al., Gene 42: 133 (1986); Bauer et al., Gene 37: 73 (1985); Craik, Biotechniques, 12-19 (January 1995); and U.S. Patent Nos. 4,518,584 and 4,737,462. The preferred way to introduce a mutation is QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, Calif., La Jolla, California).

[0300] Any suitable expression vector (e.g., as described in Pouwels et al., Cloning Vectors: A Laboratory Manual (Elsevier, NY: 1985)) and corresponding suitable host can be used to produce recombinant polypeptides. Expression hosts include, but are not limited to, bacterial species within the genera Escherichia, Bacillus, Pseudomonas, Salmonella, mammalian or insect host cell systems, including baculovirus systems (e.g., as described in Luckow et al., Bio / Technology 6: 47 (1988)), and established cell lines such as COS-7, C127, 3T3, CHO, HeLa and BHK cell lines, etc. It is known to those skilled in the art that the choice of expression host has an impact on the type of polypeptide produced. For example, the glycosylation of a polypeptide produced in yeast or mammalian cells (e.g., COS-7 cells) will be different from the glycosylation of a polypeptide produced in a bacterial cell (e.g., E. coli).

[0301] Alternatively, the polypeptides of the present invention can be synthesized using standard peptide synthesis techniques well known to those of ordinary skill in the art (e.g., as summarized in Bodanszky, Principles of Peptide Synthesis (Springer-Verlag, Heidelberg: 1984). Specifically, the polypeptides can be synthesized using solid phase synthesis procedures (see, e.g., Merrifield, J. Am. Chem. Soc. 85: 2149-54 (1963); Barany et al., Int. J. Peptide Protein Res. 30: 705-739 (1987); and U.S. Pat. No. 5,424,398). If desired, this can be accomplished using an automated peptide synthesizer. For example, removal of t-butyloxycarbonyl (t-BOC) or 9-fluorenylmethoxycarbonyl (Fmoc) amino acid blocking groups can be accomplished and the polypeptide can be separated from the resin by acid treatment at low temperatures. The polypeptide-containing mixture can then be extracted, for example, with dimethyl ether to remove non-peptide organic compounds, and the synthesized polypeptide can be extracted from the resin powder (e.g., with about 25% w / v acetic acid). After synthesis of the polypeptide, further purification (e.g., using high performance liquid chromatography (HPLC)) can optionally be performed to eliminate any incomplete polypeptides or free amino acids. The synthesized polypeptide can be subjected to amino acid and / or HPLC analysis to verify identity. For other applications according to the present invention, it may be preferred to produce the polypeptide as part of a larger fusion protein (e.g., by the methods described herein or other genetic means) or as part of a larger conjugate (e.g., by physical or chemical conjugation, as known to those of ordinary skill in the art and described herein).

[0302] In any embodiment of the present invention, the chimeric or fusion protein of the present invention may include additional amino acid residues to promote expression in a recombinant expression system and / or to promote purification of the protein. Therefore, the protein defined herein may include additional amino acids, such as one, two, three, four or five amino acids in the N-terminal region. Typically, additional amino acids will include an N-terminal methionine to promote expression in a recombinant expression system, although it should be understood that typically such N-terminal residues will be cut after translation of the protein. In certain embodiments, the N-terminal amino acid comprises at least a methionine and an alanine residue.

[0303] In addition, the chimeric or fusion protein according to the present invention may include additional amino acids in the N-terminal region or the C-terminal region, such as one, two, three, four or five amino acids, preferably to facilitate purification. It should be understood that such amino acid residues may facilitate the inclusion of purification tags (such as histidine tags, etc.) in the protein. When generating an untagged version of the protein, such residues may not be included.

[0304] The polypeptides of the invention may also be modified with, conjugated to, or fused to another moiety to facilitate purification, or to increase the in vivo half-life of the polypeptide, or for use in immunoassays using methods known in the art. For example, the polypeptides of the invention may be modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, and the like.

[0305] Nucleic Acids

[0306] Nucleic acid molecules encoding any of the chimeric or fusion proteins or polypeptides of the present invention are also within the scope of the present invention. For example, nucleic acids can be used to prepare polypeptides of the present invention and as therapeutic agents. They can be applied to cells in culture or in vivo, and can contain secretion signals that direct or promote secretion of the polypeptides of the present invention from cells. Expression vectors and host cells containing or comprising nucleic acids of the present invention are also within the scope of the present invention (described further below). Although the nucleic acids of the present invention can be referred to as "isolated", by definition, the polypeptides of the present invention are not wild-type polypeptides, and therefore will not be encoded by naturally occurring nucleic acids. Therefore, although the polypeptides and nucleic acids of the present invention can be "purified", "substantially purified" or "isolated", "recombinant" or "synthetic", in order to distinguish them from naturally occurring substances, they do not need to be so.

[0307] An "isolated" nucleic acid molecule is a nucleic acid molecule that has been identified and separated from at least one contaminant nucleic acid molecule that is typically associated with the natural source of the nucleic acid. An isolated nucleic acid molecule is different from the form or environment found in nature. Thus, an isolated nucleic acid molecule is different from its nucleic acid molecule present in natural cells. However, an isolated nucleic acid molecule comprises a nucleic acid molecule contained in a cell that typically expresses Kgp, wherein, for example, the nucleic acid molecule is located in a chromosomal position different from the position of a natural cell.

[0308] The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably herein and refer to a polymeric form of nucleotides of any length, deoxyribonucleotides or ribonucleotides, or their analogs. Non-limiting examples of polynucleotides include genes, gene fragments, messenger RNA (mRNA), cDNA, recombinant polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. The polynucleotides of the present invention can be provided in an isolated or purified form. A nucleic acid sequence "encoding" a selected polypeptide is a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of an appropriate regulatory sequence. The boundaries of the coding sequence are determined by the start codon at the 5' (amino) end and the translation stop codon at the 3' (carboxyl) end. For the purposes of the present invention, such nucleic acid sequences may include, but are not limited to, cDNA from viral, prokaryotic or eukaryotic mRNA, genomic sequences from viral or prokaryotic DNA or RNA, and even synthetic DNA sequences. The transcription termination sequence may be located at the 3' end of the coding sequence.

[0309] The polynucleotides of the present invention can be synthesized according to methods well known in the art, as described by way of example in Sambrook et al. (1989, Molecular Cloning—a laboratory manual; Cold Spring Harbor Press).

[0310] The polynucleotide molecules of the present invention can be provided in the form of an expression cassette, and the expression cassette comprises a control sequence operably connected to an insertion sequence, thereby allowing the polypeptide of the present invention to be expressed in vivo in a targeted experimenter. In turn, these expression cassettes are generally provided in a carrier (e.g., a plasmid or a recombinant viral vector) suitable for use as a reagent for nucleic acid immunization. Such expression cassettes can be directly applied to a host experimenter. Alternatively, a carrier comprising the polynucleotide of the present invention can be applied to a host experimenter. Preferably, a genetic vector is used to prepare and / or administer polynucleotides. A suitable carrier can be any carrier that can carry a sufficient amount of genetic information and allow expression of the polypeptide of the present invention.

[0311] Therefore, the present invention comprises expression vectors comprising such polynucleotide sequences. Therefore, the present invention provides a vector for preventing or treating an inflammatory disease or condition, the vector comprising a polynucleotide sequence encoding a polypeptide of the present invention and optionally one or more additional polynucleotide sequences encoding a different polypeptide as defined herein.

[0312] In addition, it should be understood that the compositions and products of the present invention may include a mixture of polypeptides and polynucleotides. Therefore, the present invention provides a composition or product as defined herein, wherein any one of the polypeptides is replaced by a polynucleotide capable of expressing a polypeptide.

[0313] Expression vectors are routinely constructed in the field of molecular biology and may, for example, involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, such as, for example, polyadenylation signals, which may be necessary and positioned in the correct orientation to allow expression of the peptides of the invention. Other suitable vectors will be apparent to those skilled in the art. As further examples in this regard, reference is made to Sambrook et al.

[0314] Therefore, the polypeptide of the present invention can be provided by delivering such vectors to cells and allowing transcription from the vector. Preferably, the polynucleotide of the present invention or the polynucleotide used in the vector of the present invention is operably linked to a control sequence capable of providing expression of the coding sequence by the host cell, i.e. the vector is an expression vector.

[0315] "Operably linked" refers to an arrangement of elements in which the components so described are configured to perform their usual functions. Thus, a given regulatory sequence (such as a promoter) operably linked to a nucleic acid sequence is capable of affecting the expression of that sequence in the presence of an appropriate enzyme. The promoter need not be adjacent to the sequence, as long as it serves to direct its expression. Thus, for example, an intermediate, untranslated, but still transcribed sequence may be present between the promoter sequence and the nucleic acid sequence, and the promoter sequence may still be considered to be "operably linked" to the coding sequence.

[0316] A variety of expression systems have been described in the art, and each expression system in the expression system is generally composed of a vector containing a gene or nucleotide sequence of interest that is operably connected to an expression control sequence. These control sequences include transcription promoter sequences and transcription start and stop sequences. The carrier of the present invention can be, for example, a plasmid, a virus or a phage vector, and the carrier is provided with a replication origin, a promoter optionally for the expression of the polynucleotide, and optionally a regulatory factor of the promoter. A "plasmid" is a carrier in the form of an extrachromosomal genetic element. The carrier can contain one or more selectable marker genes, such as an ampicillin resistance gene in a bacterial plasmid or a resistance gene of a fungal vector. The carrier can be used in vitro, for example, for the production of DNA or RNA, or for transfection or transformation of a host cell, such as a mammalian host cell. The carrier can also be suitable for use in vivo, for example, to allow the in vivo expression of a polypeptide.

[0317] A "promoter" is a nucleotide sequence that initiates and regulates transcription of a polynucleotide encoding a polypeptide. Promoters may include inducible promoters (wherein the expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), repressible promoters (wherein the expression of a polynucleotide sequence operably linked to the promoter is inhibited by an analyte, cofactor, regulatory protein, etc.), and constitutive promoters. The term "promoter" or "control element" is intended to include full-length promoter regions and functional (e.g., controlling transcription or translation) segments of these regions.

[0318] The polynucleotide, expression cassette or vector according to the present invention may additionally include a signal peptide sequence. The signal peptide sequence is usually inserted in an operably linked manner with a promoter so that the signal peptide is expressed and promotes the secretion of a polypeptide encoded by a coding sequence, which is also operably linked to a promoter.

[0319] Typically, the signal peptide sequence encodes a peptide of 10 to 30 amino acids, such as 15 to 20 amino acids. Typically, the amino acids are primarily hydrophobic. Under normal circumstances, the signal peptide targets the growing polypeptide chain carrying the signal peptide to the endoplasmic reticulum of the expressing cell. The signal peptide is cleaved in the endoplasmic reticulum, allowing the polypeptide to be secreted through the Golgi apparatus.

[0320] Immunogenicity and vaccine composition

[0321] The invention further provides compositions comprising the chimeric or fusion proteins defined herein, and the use of such chimeric or fusion proteins in immunogenic or vaccine compositions for treating or preventing Porphyromonas gingivalis infection.

[0322] As used herein, the term "vaccine composition" is defined as a composition used to elicit an immune response against an antigen (immunogen) within the composition to protect or treat an organism against disease.

[0323] As used herein, the terms "immunostimulatory composition," "vaccine composition," and "immunogenic composition" are often used interchangeably.

[0324] In addition to one or more peptides of the present invention as therapeutic or preventive active ingredients, the immunostimulatory composition or vaccine of the present invention may appropriately include a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, buffer or stabilizer. Such carriers include but are not limited to saline, buffered saline, dextrose, liposomes, water, glycerol, polyethylene glycol, ethanol and combinations thereof.

[0325] The immunostimulatory composition or vaccine composition can be suitable for administration by any appropriate route, such as parenteral (including subcutaneous, intramuscular, intravenous or intradermal or by injection into the cerebrospinal fluid), oral (including buccal or sublingual), nasal, topical (including buccal, sublingual or transdermal), vaginal or rectal routes. Such compositions can be prepared by any method known in the pharmaceutical field, such as by mixing the peptide with a carrier or excipient under aseptic conditions. Typically, the vaccine composition is suitable for administration by subcutaneous, intramuscular, intravenous or intradermal routes, typically by injection. Alternatively, the vaccine composition can be suitable for oral or nasal administration.

[0326] Immunostimulatory compositions or vaccine compositions suitable for parenteral administration can be aqueous and non-aqueous sterile injection solutions, which can contain antioxidants, buffers, antibacterial agents, and solutes that make the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which can contain suspending agents and thickening agents. Excipients that can be used for injectable solutions include, for example, water, alcohol, polyols, glycerol, and vegetable oils. Compositions can be present in unit doses or multi-dose containers, such as sealed ampoules and vials, and can be stored under freeze drying (lyophilization) conditions that only require the addition of sterile liquid carriers, such as water for injection, immediately before use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.

[0327] An immunostimulatory or vaccine composition suitable for oral administration may be presented as discrete units, such as capsules or tablets or lozenges; as a powder or granules; as a solution, syrup or suspension (in an aqueous or non-aqueous liquid; or as an edible foam or paste; or as an emulsion).

[0328] Suitable excipients for tablets or hard gelatin capsules include lactose, corn starch or its derivatives, stearic acid or its salts. Suitable excipients for use with soft gelatin capsules include, for example, vegetable oils, waxes, fats, semi-solid or liquid polyols, and the like.

[0329] For the preparation of solutions and syrups, excipients that may be used include, for example, water, polyols and sugars. For the preparation of suspensions, oils (eg, vegetable oils) may be used to provide oil-in-water or water-in-oil suspensions.

[0330] Immunostimulatory or vaccine compositions suitable for nasal administration, where the carrier is a solid, include coarse powders having a particle size, for example, in the range of 20 to 500 microns, which are administered in the manner of snuff, i.e., rapidly inhaled through the nasal passages from a powder container close to the nose. Suitable compositions for administration as nasal sprays or nose drops, where the carrier is a liquid, may include aqueous or oily solutions of the active ingredient.

[0331] Compositions suitable for administration by inhalation comprise fine particle dusts or mists which may be generated by various types of metered dose pressurized aerosols, nebulizers or insufflators.

[0332] Immunostimulatory or vaccine compositions suitable for transdermal administration can be presented as discrete patches intended to maintain close contact with the epidermis of the recipient for a long period of time. For example, the active ingredient can be delivered from the patch by iontophoresis, as generally described in Pharmaceutical Research. 3(6): 318 (1986).

[0333] Compositions suitable for topical application can be formulated as ointments, creams, suspensions, lotions, powders, solutions (e.g., mouthwashes), pastes, gels, sprays, aerosols, or oils. For infections of eyes or other external tissues (e.g., oral cavity and skin), compositions can be applied as topical ointments or creams. When formulated in ointments, active ingredients can be used together with paraffin ointment bases or water-miscible ointment bases. Alternatively, active ingredients can be formulated in emulsifiable pastes together with oil-in-water cream bases or water-in-oil bases. Pharmaceutical compositions suitable for topical application to eyes can include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, especially in an aqueous solvent. Pharmaceutical compositions suitable for topical application in the oral cavity can include lozenges, pastilles, and mouthwashes.

[0334] The immunostimulatory or vaccine composition may contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, salts (the substance of the present invention itself may be provided in the form of a pharmaceutically acceptable salt), buffers, coating agents or antioxidants.

[0335] In addition to the chimeric or fusion protein as defined herein, the vaccine composition of the invention may also contain one or more other prophylactically or therapeutically active agents.

[0336] The chimeric or fusion proteins used in the vaccine compositions of the present invention may be lyophilized or not.

[0337] In addition to the peptides as defined herein, the vaccine composition of the invention may also comprise a pharmaceutically acceptable adjuvant. An adjuvant is added to enhance the immunogenicity of the vaccine composition.

[0338] Suitable adjuvants for inclusion in the vaccine compositions are known in the art and include incomplete Freund's adjuvant, complete Freund's adjuvant, Freund's adjuvant with MDP (muramyldipeptide), alum (aluminum hydroxide), alum plus Bordatella pertussis, and immunostimulating complexes (ISCOMs, typically a matrix of Quil A containing viral proteins), QS-21, Detox-PC, MPL-SE, MoGM-CSF, TiterMax-G, CRL-1005, GERBU, TERamide, PSC97B, Adjumer, PG-026, GSK-I, GcMAF, B-alethine, MPC-026, Adjuvax, CpG ODN, Betafectin, and MF59.

[0339] The vaccine compositions of the invention may also comprise or be co-administered with one or more co-stimulatory molecules.

[0340] The dosage of the vaccine composition of the invention may vary within wide limits, depending, among other things, on the age and condition of the individual to be treated, and the physician will ultimately determine the appropriate dosage to use.

[0341] This dosage may be repeated at an appropriate frequency. For example, an initial dose of the vaccine may be administered, and then a booster administered at a later date.

[0342] For administration to mammals (particularly humans), it is expected that the daily dose of the active agent will be 1 μg / kg to 10 mg / kg body weight, typically about 10 μg / kg to 1 mg / kg body weight. In any case, the physician will determine the actual dosage that best suits the individual based on factors including age, weight, sex, and response of the individual. The above dosage is an example of a general situation. Of course, there may be situations where higher or lower dosages are a matter of course, and such dosage ranges are within the scope of the present invention.

[0343] The vaccine compositions of the invention may be administered by any convenient route as described herein, such as intramuscularly, intravenously, by inhalation, intraperitoneally or orally or by injection into the cerebrospinal fluid.

[0344] The vaccine composition of the present invention can be provided in unit dosage form, usually in a sealed container, and can be provided as part of a kit. Such kits usually (although not necessarily) include instructions for use. It can include a plurality of such unit dosage forms.

[0345] Therefore, in yet another aspect, the present invention provides a kit of parts comprising the vaccine composition of the present invention and one or more cytokines and / or adjuvants in a sealed container.

[0346] Methods for immunizing a subject using a chimeric or fusion protein of the subject

[0347] The present invention provides methods and compositions for treating, preventing or minimizing the likelihood of infection with Porphyromonas gingivalis in an individual in need thereof, the methods comprising administering a fusion or chimeric protein of the present invention.

[0348] The present invention also provides methods and compositions for inducing a humoral immune response to Porphyromonas gingivalis in a subject. The humoral response may be for the purpose of obtaining protective / therapeutic anti-Porphyromonas gingivalis antibodies directly in an individual in need of protection / therapy. Alternatively, the humoral response may be for the purpose of producing antibodies that are then isolated from the subject (or their eggs) so that the antibodies can then be directly administered to an individual in need of treatment / protection with the antibodies.

[0349] Thus, the present invention encompasses methods and compositions for preventing, minimizing the likelihood of, and / or reducing the severity and duration of a Porphyromonas gingivalis infection in a subject.

[0350] The present invention also provides a method for obtaining antibodies against Porphyromonas gingivalis, the method comprising administering the chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal. Preferably, the method further comprises isolating antibodies from the animal (e.g., from the blood of the animal) or from the egg of the animal (e.g., in the case of producing IgY antibodies from chickens).

[0351] The present invention also provides an antibody preparation comprising antibodies against Porphyromonas gingivalis, wherein the antibody preparation is obtained by administering the chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal, and isolating the antibodies from the animal or its eggs.

[0352] Antibodies against P. gingivalis can be used therapeutically to eliminate or reduce P. gingivalis infection, or prophylactically to prevent or reduce the severity of P. gingivalis infection.

[0353] As used herein, the term "treatment" or "treating" a subject includes applying or administering a composition of the invention to a subject (or applying or administering a compound of the invention to a cell or tissue from a subject) for the purpose of delaying, slowing, stabilizing, curing, healing, alleviating, relieving, altering, remediating, reducing deterioration, improving, ameliorging, or affecting a disease or condition, a symptom of a disease or condition, or the risk (or susceptibility) of a disease or condition. The term "treat" refers to any indicator of successful treatment or improvement of an injury, pathology, or condition, including any objective or subjective parameter, such as alleviation; remission; reducing the rate of deterioration; reducing the severity of the disease; stabilizing, reducing symptoms, or making an injury, pathology, or condition more tolerable to a subject; slowing the rate of deterioration or decline; making the end of deterioration less debilitating; or improving the physical or mental health of a subject.

[0354] As used herein, "preventing" or "prevention" refers to at least reducing the likelihood of acquiring the risk (or susceptibility) of a disease or condition (i.e., causing a subject who may be exposed to or susceptible to a disease but has not yet experienced or shown symptoms of the disease to not develop at least one of the clinical symptoms of the disease). Biological and physiological parameters for identifying such subjects are provided herein and are also well known to physicians.

[0355] The vaccine compositions of the invention can be administered to subjects in greatest need, such as children or the elderly or individuals at risk of exposure to P. gingivalis. The vaccine compositions of the invention can also be administered to subjects suspected of having or diagnosed with a P. gingivalis infection.

[0356] The compositions and methods of the invention extend equally to use in both human and / or veterinary medicine, the production of diagnostic agents or the production of other therapeutic agents.

[0357] As used herein, the term "subject" should be understood to mean any animal including humans, such as mammals. Exemplary subjects include, but are not limited to humans and non-human primates. For example, the subject can be a human. In another example, the subject can be a veterinary subject, such as a companion animal (cat, dog, guinea pig, etc.). As used herein, the terms "subject," "individual," and "patient" can be used interchangeably.

[0358] Those skilled in the art will be familiar with methods for determining successful vaccination / immunization with a chimeric or fusion protein or composition as described herein. For example, those skilled in the art will be familiar with methods for quantifying antibodies produced after immunization and / or for quantifying the extent of humoral (Th2) responses induced after immunization.

[0359] Reagent test kit

[0360] In another embodiment, a kit or article of manufacture is provided, comprising one or more proteins, polypeptides or polynucleotides of the invention and / or the immunogenic composition as described above.

[0361] In yet another aspect, the present invention provides a kit of parts comprising the vaccine composition of the present invention and one or more adjuvants for separate, subsequent or simultaneous administration to a subject.

[0362] In other embodiments, a kit for the above-mentioned treatment or prevention application is provided, the kit comprising:

[0363] - a container containing a protein, polypeptide, polynucleotide or immunogenic composition of the invention;

[0364] - Label or package insert with instructions for use.

[0365] In any embodiment, the kit may contain one or more additional active principles or ingredients for eliciting an immune response to Porphyromonas gingivalis in a subject.

[0366] Kits or "articles of manufacture" may include containers and labels or package inserts on or associated with the containers. Suitable containers include, for example, bottles, vials, syringes, blister packs, etc. The container may be formed of a variety of materials, such as glass or plastic. The container holds a therapeutic composition for effectively treating a condition and may have a sterile access port (e.g., a container may be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). The label or package insert indicates that the therapeutic composition is used to treat the selected condition. In one embodiment, the label or package insert includes instructions for use and indicates that the therapeutic or preventive composition may be used to treat an inflammatory disease or condition described herein.

[0367] The kit may include (a) a therapeutic or preventive composition; and (b) a second container containing a second active principle or ingredient. The kit in this embodiment of the invention may further include a package insert indicating that the composition and other active ingredients can be used to treat a condition or prevent complications from an inflammatory disease or condition described herein. Alternatively or in addition, the kit may further include a second (or third) container including a pharmaceutically acceptable buffer such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desired from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.

[0368] In any embodiment, the therapeutic composition can be provided in the form of a disposable or reusable device, comprising a container for holding a therapeutic, preventive or immunogenic composition. In one embodiment, the device is a syringe, an automatic injector or a nanopatch. The device can hold 0.1 to 2 mL of a therapeutic or immunogenic composition. The therapeutic or preventive composition can be provided in the device in a state ready for use or in a state requiring mixing, dissolving or resuspending or adding additional components.

[0369] It should be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the various features mentioned or evident in the text or drawings. All these different combinations constitute various alternative aspects of the invention.

[0370] The following examples are described to more fully illustrate some embodiments of the present invention. However, the examples should never be interpreted as limiting the broad scope of the present invention. Those skilled in the art can easily design many variations and modifications of the principles disclosed herein without departing from the scope of the present invention.

[0371] Examples

[0372] The following examples describe a series of in vitro and in vivo studies related to the chimeric or fusion proteins of the present invention. Example 1 describes the materials and methods used in the studies described in Examples 2 and 3. Example 2 describes the results of the in vitro studies, and Example 3 describes the results of the in vivo studies.

[0373] Example 1: Method

[0374] 1.1 Materials and methods for in vitro studies

[0375] Expression of recombinant proteins

[0376] Recombinant proteins (ie, various chimeric or fusion proteins as described herein) were expressed from pET28 vectors (or pDUET-1 for co-expression of rABM1+rABM2 from one vector) by induction with isopropyl β-D-thiogalactosidase (IPTG), essentially as follows.

[0377] Nucleic acids encoding different chimeras and components of chimeras and fusion proteins (comprising active site and adhesin domains) were generated by DNA splicing using Porphyromonas gingivalis W50 genomic DNA template and specially designed oligonucleotide primers by standard PCR or overlap extension ("SOEing") PCR. PCR fragments or SOEn PCR fragments were purified and ligated into cloning vectors pGEMTeasy or pBHA and transformed into chemically competent E. coli α-Gold cells (Bioline, New South Wales, Australia).

[0378] DNA sequences encoding single additional KAS (i.e., active site) residues (with or without a "DSSG" amino acid linker region) were sequentially added to the recombinant chimera and Kgp adhesin domains, one at a time, essentially as follows: restriction enzyme sites were introduced into the ends of the DNA inserts in the chimera and adhesin variant mother clones by PCR using oligonucleotide primers containing nucleotides specific for restriction enzymes. Synthetic DNA fragments encoding a single KAS sequence with the corresponding restriction sequence were ligated to the insert ends of the DNA constructs from the mother clones, and the recombinant clones were purified. Subsequently, if a second or third additional KAS was added, additional restriction sequences were introduced into the ends of these clone inserts, and additional DNA fragments encoding KAS sequences with different restriction sites were ligated one at a time. Mother clone constructs with single, bi-, or quadrilinear KAS coding sequences were subjected to specific restriction digests, and then the subfragments were interchanged by ligation to generate a variety of variants (including those exemplified in Table 1).

[0379] Residues within ABM1 and ABM2 as well as cysteine ​​residues were mutated using the QuickChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA) following the manufacturer's instructions.

[0380] The integrity of each insertion in the cloning vectors pGEMTeasy and pBH1 was confirmed by DNA sequencing (Applied Genetics and Diagnostics Facility, The University of Melbourne). The mutation was further verified by DNA sequencing of the entire insertion. The verified construct was then subjected to restrictive digestion with a selection enzyme, and the insertion was cloned into the relevant pET expression vector in the E. coli α selection chemical competent cells, and subsequently cloned into the E. coli expression host BL21-CodonPlus (DE3) RIPL (Stratagene, Australia).

[0381] Study of the characteristics of chimeras that affect the solubility of recombinant proteins; small scale

[0382] Use single colony transformants to inoculate 2mL of Luria Bertani (LB) broth containing 30μg / ml kanamycin on an orbital shaker at 37°C overnight. Then use this inoculum to inoculate (1:100) 2ml of LB containing 30μg / ml kanamycin. Induce cell culture of OD600=0.6-1.0 with 1mM IPTG for 2 hours at 37°C. The cell culture is centrifuged and the pellet is resuspended in 250μl PBS and briefly sonicated and centrifuged using a CPX750 ultrasonic processor (Cole Parmer Instrument Company, USA).

[0383] Total lysate, soluble (supernatant) and insoluble (pellet) fractions are analyzed by SDS-PAGE to assess the solubility of recombinant protein. Under these initial pilot expression conditions, insoluble or low-solubility recombinant proteins are expressed under various relatively low temperatures (16 ℃ to 30 ℃) and relatively low IPTG (0.01-0.5mM) to determine the best conditions to improve solubility. Under the best conditions, all recombinant protein inductions are amplified (20-200ml) to test medium-large-scale solubility. Cultures (200mL) are subjected to IPTG induction at different temperatures (for example, 5 hours at 30 ℃ or 16 hours at 16 ℃).

[0384] Cells were harvested and resuspended in lysis buffer (20 mM sodium phosphate, 500 mM NaCl, 0.5% v / v Triton X-100, 5 mg / ml DNAseI, 1X protease inhibitor cocktail, 1 mg / ml lysozyme, 10 mM imidazole, pH 8). The cell resuspension was incubated at 4°C for 1 hour, and the clarified lysate was then centrifuged (8,000 ɡ, 30 minutes, 4°C) to collect the supernatant (soluble) and pellet (insoluble) fractions, and analyzed by SDS- and native-PAGE.

[0385] In-gel HIS staining of recombinant proteins

[0386] According to the manufacturer's instructions, the recombinant proteins subjected to SDS PAGE were stained using the Invision In-Gel His Staining Kit (Invitrogen). This staining is highly specific for His-tagged proteins. This procedure was used to identify N-terminal degradation of recombinant proteins, as all candidates contained a C-terminal His tag.

[0387] Large-scale purification of chimeras for animal model studies

[0388] The purification conditions for each recombinant protein are detailed in the following sections.

[0389] Protein expression and cell lysis

[0390] As previously described, all recombinant proteins identified for use as animal model vaccine candidates were expressed as recombinant C-terminal His-tagged fusion proteins or "tag-free" proteins in E. coli BL21 (DE3). Cells were grown at 37° C. in LB medium, TB medium, or modified M9 minimal medium supplemented with 50 μg / mL kanamycin. Cultures with OD600=0.8-1.0 were induced with 0.4 mM IPTG for 2-4 hours at 37° C. or 34° C., 12 hours at 25° C., or 16-20 hours at 16° C. After harvesting by centrifugation at 8000 g at 4°C, cells were lysed on ice for 1.5 hours in lysis buffer [0.35 mg / mL lysozyme, 40 μg / mL DNase I in TBS150 (50 mM Tris·Cl, 150 mM NaCl, pH 7.5)] plus 1% Triton X-100 and EDTA-free protease inhibitors (Complete ULTRATablets, Sigma-Aldrich), unless otherwise stated. Cell lysates were clarified by centrifugation at 23,500 g for 40 minutes at 4°C.

[0391] The initiator Met residue (aa 1) on all recombinant proteins shown in Table 1 (starting from the translation sequence MA) was removed in vivo by the E. coli N-terminal methionine processing enzyme (which cleaves methionine when the penultimate residue is a small residue). This was confirmed by mass spectrometry analysis of the recombinant proteins of KDAK and KDAK variants.

[0392] Purification of His-tagged proteins from the soluble fraction under native conditions

[0393] 1. Ni affinity chromatography

[0394] The cell lysate was clarified by centrifugation at 20,000 g at 4 ° C to remove cell debris. After filtering through a 0.22 μm filter, the lysate was loaded onto a HisTrap Ni affinity column (GE Healthcare) in loading buffer TBS300 (50 mM Tris Cl, 300 mM NaCl, pH 7.5) plus 10 mM imidazole and 1% Triton X-100. The column was washed thoroughly with loading buffer and then washed in 20 mM imidazole in TBS300. The bound protein was eluted with a 20-350 mM imidazole gradient in TBS300, and the absorbance was monitored at 280 nm. The peak fractions were analyzed with SDS- and / or native PAGE. The eluted target protein was concentrated using an Amicon filtration unit, with a molecular weight cutoff of 3 kDa or 10 kDa depending on the protein size. The resulting protein solution was stored at -70 ° C for further purification.

[0395] 2. Anion Exchange Chromatography

[0396] The isoelectric points (pI) of all candidate proteins were predicted to be in the acidic range using the online analytical ProtParam tool – ExPASy (https: / / web.expasy.org / protparam / ), so anion exchange chromatography was applied for further purification when necessary. Briefly, the concentrated protein from Ni affinity purification was diluted into buffer A (50 mM Tris.Cl, 20 mM NaCl, pH 7.5) to reduce the ionic strength and then loaded into an anion exchange HiTrap Q column (GE Healthcare) in buffer A. The protein was eluted with a NaCl gradient from 20 to 400 mM in Tris buffer, monitoring the absorbance at 280 nm. The target protein in the peak fraction was verified by SDS- and / or native PAGE and concentrated using an Amicon filtration unit with an appropriate molecular weight cutoff. The protein solution was stored at -70 °C for further purification or buffer exchange using size exclusion chromatography or dialysis.

[0397] 3. Size Exclusion Chromatography

[0398] Size exclusion chromatography was performed on a HiLoad Superdex 200 or HiLoad Superdex 75 column (GE Healthcare) at 4°C. The proteins from the further steps of Ni affinity purification or anion exchange chromatography were loaded into appropriate columns and eluted in TBS150 or TBS100 buffer (100 mM NaCl in 50 mM Tris.Cl, pH 7.5), monitoring the absorbance at 280 nm. The target protein in the peak fraction was verified by SDS- and / or native PAGE. In order to separate single oligomeric species, such as dimers, a second or further round of size exclusion purification was performed. The fractions containing the best protein purity were pooled and concentrated. In order to prepare a mixture of protein homopolymers, the target protein fractions were simply pooled and concentrated. When necessary, protein identity was confirmed by determining intact protein molar mass by liquid chromatography-electrospray ionization spectrometry (LC-MS, Agilent) or sequence analysis by liquid chromatography-Orbitrap tandem mass spectrometry (LC-MS / MS, Agilent). Protein concentration was quantified by determining absorbance at 280 nm using the calculated extinction coefficient prior to submission for animal model experiments.

[0399] Purification of His-tagged proteins from inclusion bodies

[0400] 1. Under oxidative conditions

[0401] After cell lysis (as described for purification from soluble fraction), insoluble pellets were washed twice with TBS150. The protein expressed as inclusion bodies was dissolved 1 hour at room temperature on a rolling platform with 8M urea in TBS300 or 20mM NaPi, 500mM NaCl, pH 7.4 (PBS500). Protein extract was centrifuged at 20,000g and filtered by 0.22 μm filter unit, and then loaded into the HisTrap affinity column in the buffer TBSU (8M urea in TBS300 plus 20mM imidazoles) or PBSU (8M urea, 20mM NaPi, pH 7.8, 500mM NaCl plus 20mM imidazoles) containing urea. The column was fully washed with the same 8M urea buffer. Further washing with PBSU at pH 6.5 was applied to the column with protein loaded in PBSU. In order to remove urea, the target protein is eluted with the gradient of 20-500mM imidazoles in PBSU. When using loose Ni-NTA resin (Thermofisher), urea extract is mixed with resin for 2 hours while stirring gently in PBSU. After fully washing with PBSU (pH 7.8, and then pH 6.5), and eluting the protein bound from resin in the same buffer with 500mM imidazoles. The protein of wash-out is progressively dialyzed into 6M, 4M and then 2M urea phosphate buffer in the dialysis tubing with a molecular weight cutoff of 3.5kDa (FisherBiotec, Australia). Before submitting to animal model experiments, the protein in 2M urea buffer is further dialyzed into saline, and maintained at 4°C, or submitted to 2M urea buffer without further dialysing.

[0402] 2. Under reducing conditions

[0403] In the presence of 5mM TCEP, protein is extracted from inclusion bodies with 6M urea buffer and loaded onto a HisTrap column in the same buffer. After washing the column with a 4M urea buffer containing 2M TCEP, the target protein is refolded with a concentration gradient of urea from 4 to 0M on the column in the presence of 2M TCEP. Then, in TBS300 plus 2mM TCEP, the protein is eluted with an imidazole elution gradient of an increase of 20-350mM. Then, in the same manner as described in the chapters of purifying protein dimers or polymers from soluble fractions under non-denaturing conditions, the eluted protein is then concentrated in a reducing buffer (2mM TCEP in TBS150) to perform size exclusion chromatography. After SDS- and native PAGE, mass spectrometry and quantitative analysis, the sample is stored in a reducing buffer at -70°C or submitted for animal model experiments.

[0404] Purification of His-tagged proteins from the soluble fraction under oxidative and denaturing conditions

[0405] The cell lysate was clarified by centrifugation at 20,000 g to remove debris and insoluble material, and then the lysate was immediately denatured to a final concentration of 8 M by adding urea solution in PBS500 and stirred for 1 hour at room temperature. The resulting lysate was then centrifuged at 20,000 g for 40 minutes at room temperature. The target protein was purified using a HisTrap Ni affinity column or loose Ni-NTA resin in the same manner as described in the section Purification from inclusion bodies-oxidative conditions above. The purified antigen in saline was stored at 4°C before submission for animal model experiments.

[0406] Purification of tag-free candidates from the soluble fraction

[0407] Anion exchange chromatography This is the first chromatographic step for the purification of tag-free proteins. Like its His-tagged counterpart, the pI of the tag-free candidate was predicted to be in the acidic range using the online analytical ProtParam tool – ExPASy (https: / / web.expasy.org / protparam / ). Therefore, anion exchange chromatography was applied and two rounds were performed. In the first round, the clarified cell lysate was filtered through a 0.22 μm filter disk and loaded onto an anion exchange HiTrap Q column (GE Healthcare) in buffer AA (20 mM NaPi, pH 6.5, supplemented with 0.05x protease inhibitor cocktail). After washing with 10 column volumes of buffer AA, the bound protein was eluted with a NaCl gradient of 0-100% of buffer BA (1 M NaCl in 20 mM NaPi, pH 6.5) and the absorbance at 280 nm was monitored. The target protein in the peak fraction was verified by SDS- and / or native PAGE. In the second round, the best fractions from the anion exchange step of the first round were pooled and diluted 6-fold with buffer AA and then reloaded into an anion exchange HiTrap Q column (GE Healthcare) in the same buffer. The bound protein was eluted with a 0-50% NaCl gradient in buffer BA, monitoring the absorbance at 280 nm. The target protein in the peak fraction was verified by SDS- and / or native PAGE, and the best fractions were concentrated using an Amicon filtration unit with a 10 kDa molecular weight cutoff. The protein solution was stored at -20°C for further purification by size exclusion chromatography.

[0408] First round of size exclusion chromatographySize exclusion chromatography was performed on a HiLoad Superdex 200 column (GE Healthcare) at room temperature. Proteins from the purification by anion exchange chromatography were loaded into a size exclusion column and eluted in AS buffer (1M (NH4)2SO4, 50mM NaPi, pH 7.0, supplemented with 0.05x protease inhibitor cocktail), monitoring absorbance at 280nm. The target protein in the peak fractions was verified by SDS- and / or native PAGE. The fractions of optimal protein purity were pooled for further purification by hydrophobic interaction chromatography.

[0409] Hydrophobic Interaction Chromatography Pooled fractions of the target protein in buffer AS from the first round of size exclusion chromatography were filtered through a 0.22 μm membrane and loaded onto a HiTrap Phenyl HP column pre-equilibrated in buffer AH (1 M (NH4)2SO4, 50 mM NaPi, pH 7) at 4°C. The bound protein was eluted with a gradient of decreasing ionic strength from 800 mM to 200 mM (NH4)2SO4 in buffer BH (50 mM NaPi, pH 7), monitoring the absorbance at 280 nm. The target protein in the peak fractions was verified by SDS- and / or native PAGE and the best fractions were pooled and concentrated using an Amicon filtration unit for the next purification or a buffer exchange step for a second round of size exclusion chromatography.

[0410] Second round of size exclusion chromatography The concentrated sample from the purification step with hydrophobic interaction is loaded into a size exclusion column as used in the first round of size exclusion chromatography and eluted in a buffer of BTS (20 mM Bis-Tris, 150 mM NaCl, pH 6.5). The peak fractions are analyzed with SDS- and / or native PAGE. The fractions of optimal purity are pooled and concentrated. After identification and quantification with liquid chromatography-electrospray ionization mass spectrometry (LC-MS, Agilent), the antigens are aliquoted and stored at -80 °C for future use.

[0411] Protein identification and quantification of label-free candidates

[0412] In addition to SDS- or native PAGE verification, protein identity was confirmed by determining intact protein molar mass using LC-MS or by sequence analysis using liquid chromatography Orbitrap tandem mass spectrometry (LC-MS / MS, Agilent) when necessary. Protein concentration was quantified by determining absorbance at 280 nm using calculated extinction coefficients (Table 3). In cases where buffer exchange was required prior to submission for animal model experiments, a Superdex 200 size exclusion column (GE Healthcare) or a Zeba TMSpin Desalting Column (ThermoFisher Scientific).

[0413] 1.2 Materials and methods for in vivo studies

[0414] Bacterial Culture in the Mouse Model of Periodontitis

[0415] Porphyromonas gingivalis strain; W50 (serotype C) was obtained from the culture collection of the Oral Health Cooperative Research Centre, The Melbourne Dental School, University of Melbourne, Australia. Porphyromonas gingivalis W50 was grown on horse blood agar (HBA) (20 g / L HBA; Oxoid Ltd., Hampshire, UK) supplemented with 10% v / v lysed horse blood (37° C.) in an anaerobic N atmosphere containing 5% CO in a MK3 anaerobic workstation (Don Whitley Scientific Ltd., Adelaide, Australia). The colony was inoculated into a starter culture containing 20 mL of sterile brain heart infusion (37 g / L BHI; Oxoid, Hampshire, England) medium supplemented with 5 mg / L heme and 0.5 mg / L cysteine ​​[McKee et al. (1986) Infect Immun 52:349-355] and incubated anaerobically (24 hours, 37°C). The absorbance of the batch culture was monitored at OD650nm using a spectrophotometer (Model 295E, Perkin-Elmer, Germany). Bacterial cells were harvested during late exponential growth by centrifugation (7,000 g, 20 minutes, 4°C). Bacterial purity was routinely confirmed by Gram staining [Slots (1982). Host-Parasite Interaction in Periodontal. Genco, RJ and Merganhagan, SE (eds.). Washington DC: American Society for Microbiology. pp. 27-45].

[0416] Preparation of heat-killed bacteria

[0417] Porphyromonas gingivalis W50 culture (6,500g, 4°C) was collected, washed once with phosphate buffered saline (PBS) (0.01M Na2HPO4, 1.5mM KH2PO4 and 0.15M NaCl, pH 7.4), and then pelleted by centrifugation (7,000g, 20 minutes, 4°C). The bacterial cells were resuspended in PBS and heated to 65°C for 15 minutes. The suspension was centrifuged (7,000g, 20 minutes, 4°C) and resuspended in sterile PBS, and this was repeated once. After the second wash, the supernatant was discarded and the cell pellet was resuspended in sterile PBS to obtain 2×10 10 Cell densities were determined at 10 cells / mL and protein concentrations were determined using Biorad protein assay dye reagent concentrate (Life Science, NSW, Australia).

[0418] Mouse periodontitis model

[0419] The mouse periodontitis experiment was modified from the model of Baker et al. (1994). Arch Oral Biol 39:1035-1040 and performed as previously described by O'Brien-Simpson et al. (2005 J Immunol 175:3980-3989). On day 0, mice (female BALB / c; 6-8 weeks old, 10 mice / group) were intraorally inoculated with four doses of Porphyromonas gingivalis W50 [1×10 10 gingivalis] composed of 10 live Porphyromonas gingivalis W50 cells suspended in 20 μL PG buffer (50 mM Tris-HCL, 150 mM NaCl, 10 mM MgSO4 and 14.3 mM mercaptoethanol, pH 7.4) containing 2% w / v carboxymethylcellulose (CMC, Sigma, New South Wales, Australia) and given at two-day intervals. The inoculum was prepared anaerobically and then immediately applied to the gingival margin of the maxillary molars. The number of viable bacteria in each inoculum was verified by flow cytometry and CFU counting on blood agar. Animal groups consisted of: an orally inoculated Porphyromonas gingivalis W50 (infected control) group, a non-bacterial inoculated control group and an immunized group. For the therapeutic vaccination periodontitis model ( Figure 1), mice were immunized by intraperitoneal route on day 19 after the first oral vaccination with 50 μg of the vaccine candidate in saline / alum (alveol; 2% aluminum hydroxide wet gel suspension; Invivogen). On day 40, mice received a second immunization by subcutaneous route (50 μg in saline / alum). On day 62, mice were bled by cardiac puncture and killed. The maxilla was removed and split in half through the midline, and 10 halves were used to determine alveolar bone loss. The serum was used to determine the antibody profile using ELISA.

[0420] Measurement of alveolar bone loss in the mouse maxilla

[0421] The maxillary bones to be examined for bone loss were boiled in deionized water (1 minute), mechanically fleshed and immersed in 2% w / v potassium hydroxide (16 hours, 25°C). The maxillary bones were washed twice with deionized water (25°C), dried (1 hour, 37°C) and stained with 0.5% w / v methylene blue aqueous solution. Digital images of the buccal side of the maxillary bones were taken with an Olympus DP12 digital camera mounted on a dissecting microscope using OLYSIA BioReport software version 3.2 (Olympus Australia Pty Ltd, New South Wales, Australia) to assess horizontal bone loss. The maxillary bones were oriented so that the buccal and lingual molar tips overlapped. Images were captured in microns in the frame so that the measurements could be standardized for each image. Horizontal bone loss is defined as bone loss that occurs in a horizontal plane perpendicular to the alveolar bone ridge, causing a decrease in ridge height. The visible area from the cementoenamel junction (CEJ) to the alveolar bone crest (ABC) of each molar was measured using OLYSIA BioReport software version 3.2. 2 Total visible CEJ-ABC area is given in units of 4. 2 The total visible CEJ-ABC area (in mm) was calculated by subtracting the total visible CEJ-ABC area of ​​the non-vaccinated (NC) group from the total visible CEJ-ABC area of ​​each experimental group. Alveolar bone loss measurements were determined twice in a randomized and blinded protocol. Data are presented as mean + / - standard deviation (in mm 2 The data were expressed as units and analyzed using one-way ANOVA and Dunnett's T3 post hoc test.

[0422] Pre-screening of vaccine candidates by enzyme-linked immunosorbent assay (ELISA)

[0423] Vaccine candidates were pre-screened using several monoclonal antibodies against Porphyromonas gingivalis to determine whether the major domains and epitopes present in the vaccine constructs were accessible to antibodies, thereby generating an antibody response in vivo. The antigens to be screened were coated in 0.1M PBS (pH 7.4) onto flat-bottomed polyethylene microtiter plates (Microtiter; Dynatech Laboratories, McLean, VA, US) for 16 hours at 4°C. In these experiments, the following antibody dilutions were used: 1 / 4000 dilution of goat anti-mouse; IgG (M8642) antibody (Sigma, New South Wales, Australia). 1 / 4000 dilution of horseradish peroxidase-conjugated porcine anti-goat IgG antibody (M5420; Sigma, New South Wales, Australia) was used to develop ELISA experiments.

[0424] Determination of antibody subclasses in serum using ELISA

[0425] As described by Pathirana et al. (2007). Infection and Immunity 75: 1436-1442, ELISA was performed to evaluate subclass antibodies in serum, using HK W50 cells in 0.1M PBS (pH 7.4), solutions of domain subunits or epitopes (1 μg / mL) to coat the wells of flat-bottom polyethylene microtiter plates (Microtiter; Dyna Scientific, McLean, VA, USA) (16 hours, 4°C). In these experiments, the following antibody dilutions were used: 1 / 4000 dilution of goat anti-mouse; IgG (M8642), IgG1 (M8770), IgG2a (M4434) antibodies (Sigma, New South Wales, Australia). A 1 / 4000 dilution of horseradish peroxidase-conjugated porcine anti-goat IgG antibody (M5420; Sigma, New South Wales, Australia) was used to develop the ELISA experiment. For epitope ELISA, biotinylated peptides were bound to pre-blocked streptavidin-coated flat-bottom plates (Pierce; Thermo Fisher Scientific) at 10 μg / mL. After incubation with serum, ELISA was developed with 1 / 4000 goat anti-mouse IgG and 1 / 4000 horseradish peroxidase-conjugated pig anti-goat IgG antibodies. All optical density measurements were performed at 405 nm on a Wallac VICTOR3 1420 Multilabel counter (Perkin Elmer).

[0426] Example 2: Results of in vitro studies

[0427] Study 1: Effects of chimera components on the solubility of recombinant proteins

[0428] A previously reported chimera (in WO 2010 / 022463) consists of a KAS (K) peptide conjugated to an N-terminally truncated DUF2436 domain (Dc), an adhesin domain including ABMs213 (A), and a C-terminally truncated CAD domain (truncated K1 domain, referred to as K1n). This chimera is referred to as "KDcAK1n" (SEQ ID NO: 54) and may be referred to herein as the "original chimera" or "chimera" in comparison to the chimeric and fusion proteins of the present invention. The KDcAK1n protein is produced as inclusion bodies in E. coli and has poor solubility and poor stability.

[0429] The truncated DUF and K1 domains of the A1 adhesin fragment represent how the Kgp polyprotein is natively proteolytically processed and assembled on the P. gingivalis cell surface during infection. Therefore, the truncated DUF and K1 domains are obvious candidates for inclusion in vaccines to generate an immune response to gingipains.

[0430] Numerous attempts were made to generate soluble KDcAK1n. Extensive testing of changes in growth media, growth conditions, IPTG concentration, E. coli expression strain, induction temperature, cell growth phase at induction, addition of growth stabilizers, lysis buffer, and protein storage buffer were systematically investigated. Enhancement of soluble recombinant protein expression was observed in small-scale expression at low temperature and IPTG induction. At small scale, KDcAK1n produced approximately 30-50% of the total recombinant protein expression as soluble protein. However, soluble recombinant could not be scaled up to cultures larger than 10 ml, resulting in the formation of inclusion bodies with any attempt to scale up.

[0431] Effect of DUF domain on protein solubility

[0432] Truncation of the DUF domain in the chimeric protein construct resulted in abrogation of soluble protein expression. This result suggests that an intact DUF domain containing the additional 38 N-terminal residues is desirable for optimizing soluble expression and efficient stabilization of recombinant proteins.

[0433] Therefore, a construct was created to express a chimeric variant with an extended Dc domain (a chimera with Dc extended by 38 N-terminal residues). This recombinant was named KDAK1n (e.g., SEQ ID NO: 55), and the results showed that the chimera with an intact DUF domain had significantly improved solubility. Large-scale expression of KDAK1n at 30°C with 0.2-0.5 mM IPTG resulted in expression of a good yield of soluble recombinant protein.

[0434] To summarize:

[0435] ● Full-length DUF domain is desirable for solubility of recombinant variants ( Figure 2 A)

[0436] Therefore, extending the DUF to full length is important for the solubility and stability of recombinant proteins.

[0437] Study 2: Factors affecting multimerization

[0438] Native PAGE analysis of purified soluble DUF-ABM213 and ABM213 and ABM21 recombinant proteins resulted in extensive and even step-like multimerization indicative of multimerization. Multimerization was also evident in prior art KDcAK1n chimeras via intermolecular disulfide bond formation between denatured domains. Such disulfide-linked multimers were most evident in KDcAK1n chimeras purified from inclusion bodies.

[0439] During the course of studies of recombinant chimeras and Kgp adhesins, it became apparent that multimerization of the recombinant proteins occurs via interactions between the ABM1 and ABM2 motifs. Recombinant proteins containing ABM2(1), ABM2(2), and ABM3 domains (ref. Figure 3 The following expression of a smaller recombinant protein encoding ABM2(1), ABM1(2), and ABM3 (designated rABM213) and a recombinant protein encoding ABM2(1) and ABM1(2) (designated rABM21) showed that both recombinants were able to readily multimerize. This multimerization was evident by the appearance of a neat ladder of bands on native PAGE.

[0440] It is proposed that during the folding of the Kgp multidomain polyprotein, the ABM1 domain interacts with the ABM2 domain to form an FnIII-like stable β-sheet complex structure. The inventors hypothesize that during the folding of the Kgp polyprotein, ABM1 (1) will interact with its next available neighbor ABM2 (1), and ABM1 (2) will interact with ABM2 (2), and so on (e.g. Figure 3 A schematically depicted).

[0441] In separate studies, the inventors showed that rABM1 and rABM2, co-expressed as separate proteins, are able to interact to form a stable β-sheet complex structure. rABM2 (1) is able to form a stable structure with either rABM1 (1) or rABM1 (2). More specifically, NMR spectroscopic analysis of the folded ABM domain indicated that the domain multimerizes via β-strand exchange involving the ABM1 and ABM2 motifs. Together, these results provide evidence that chimeras and variants containing the ABM domain will multimerize via interactions between the ABM1 and ABM2 motifs of a properly folded ABM domain.

[0442] Subsequently, the inventors aimed to mutate specific residues of ABM1 or ABM2 in the recombinant ABM21 (rABM21) protein, which covers residues 878-968 on the Kgp W50 polyprotein.

[0443] BLAST analysis of Kgp ABM1 and ABM2 sequences in all available bacterial genomes revealed that submotifs within the ABM1 and ABM2 motifs were highly conserved across all phyla. Subsequently, alignment of the ABM1 and ABM2 sequences with all ORFs within the W83 genome revealed that these residues were similarly highly conserved in Porphyromonas gingivalis genes. The "PVQN" motif with a conserved proline residue was highly conserved across phyla, including Porphyromonas gingivalis.

[0444] Molecular modeling of the proposed tertiary fold using an online program revealed that this "PVQN" sequence is located at the beginning of the β-sheet structure, and the sequence immediately N-terminal to this motif was found to be most likely an unstructured "loop".

[0445] The inventors mutated residues within the PVQN motif of rABM21 as well as residues within the loop immediately preceding PVQN. Residues within the loop were targeted because it is believed that the size and shape of the loop preceding the beta sheet structure can affect the strength of the adjacent beta sheet fold. The number and position of proline residues within such "loop" structures were reported to correlate with adjacent beta sheet interactions.

[0446] In addition, the inventors mutated the highly conserved hydrophobic residues Y (878) and W (968) present in ABM2 and ABM1, respectively. The inventors also introduced the substitution of SxYQ into the sequence of the motif NxFA in the ABM1 sequence (see SSEYQ variants mentioned in Table 2 below).

[0447] Mutated rABM21 variants were purified and their ability to multimerize was assessed.The inventors sought to identify mutations that would result in stable soluble recombinant molecules that could be purified as stable monomers.

[0448] Table 2: Summary of the solubility and ability to form multimers of recombinant proteins on native-PAGE in the presence or absence of DTT. (N / T = not tested)

[0449]

[0450] All recombinant proteins (WT rABM213, rABM21, and rABM21 mutant variants) resulted in very high levels of expression of highly soluble recombinant proteins under poor induction conditions (summarized in Table 2).

[0451] Purified recombinant protein subjected to native Page analysis ( Figure 3 BE) showed that rABM21 can form multimers through two mechanisms: (1) multimerization through the ABM1 motif "PVQN" and (2) multimerization through disulfide bonds.

[0452] Mutation of the highly conserved "PVQN" motif in rABM21 to AVQN or AVQA did not abolish multimerization.

[0453] Mutation of "PVQN" to AVQP caused a significant reduction in multimerization in the presence of DTT, and a slight reduction in multimerization in the absence of DTT, indicating that the change from PVQN to AVQP alone has some effect in reducing multimerization.

[0454] The AVQA mutation combined with substitution of one or both cysteine ​​residues in the ABM domain to serine caused a slight reduction in multimerization.

[0455] Mutation of "PVQN" to AVQP and mutation of one or both cysteine ​​residues in the ABM domain to serine together resulted in near or complete abrogation of rABM21 multimerization.

[0456] Manipulation and mutation of residues in the modeled "loop" region directly before the ABM1 "PVQN" motif of the modeled "β-sheet region" was also able to reduce multimerization, but could not completely eliminate it. More specifically, "SSEYQ" substitutions in ABM1 (e.g., modifying the sequence SNEFA to SSEYQ (immediately N-terminal to the highly conserved PVQN motif)) resulted in a significant reduction in multimerization.

[0457] Mutation of the Tyr-889 and Trp-964 residues (in ABM2 and 1, respectively) also together resulted in abrogation of multimerization of rABM21.

[0458] Manipulation of the "PVQN" motif to AVQP together with substitution of cysteine ​​residues within the ABM domain enabled expression and purification of a very highly soluble monomeric protein using the E. coli pET expression system.

[0459] All chimeric candidates consisting of the original sequence with two cysteine ​​residues within the complete ABM21 domain exhibited extensive ladder-like multimerization ( Figure 3 B and C). However, substitution of these two cysteine ​​residues did not completely abolish ladder-like multimerization ( Figure 3 C lanes 15 and 16), although substitution of one cysteine ​​residue combined with the AVQP substitution provided a significant reduction in multimerization. Complete abolition of ladder-like multimerization was only achieved by removing both ABM cysteine ​​residues plus changing the motif PVQN to AVQP. This suggests that the cysteine ​​residues in the DUF domain (which were not substituted in these experiments) are not important triggers for multimerization.

[0460] Although changes in cysteine ​​residues and the PVQN motif disabled ladder-like multimerization, an equilibrium between monomeric and oligomeric states still existed under certain conditions. This equilibrium was found to be temperature, pH, and concentration dependent by analysis using size exclusion chromatography. Increased temperature, decreased pH, and decreased concentration were found to favor the monomeric state. The presence of the His tag was not responsible for the equilibrium of protein states. SEC-MALS analysis showed that monomers were overwhelmingly present in solutions at concentrations of 2 mg / mL or less, where the lead candidate had high stability.

[0461] Study 3: Active site (KAS) motif

[0462] Additional KAS motifs were engineered into the recombinant chimeric variants to determine whether this would have an impact on immunogenicity. A single KAS or two consecutive KAS were added to the N-terminal or both ends of the variant. In addition, a linear sequence of 4 KAS residues containing a DSSG linker sequence between each KAS motif was added to the N-terminal of the selected variant.

[0463] The purification curve of recombinant and His gel staining analysis revealed that additional KAS residues caused some instability and degradation of recombinant protein. The degradation and instability of 4x linear KAS variants were the greatest, indicating that proteolytic processing occurred in additional KAS sequences. The subsequent removal of the DSSG linker between adjacent KAS sequences did not improve stability.

[0464] It was therefore concluded that these variants were susceptible to proteolytic processing when consecutive multiple KAS sequences were expressed in a linear sequence. Soluble variants with a single KAS at one or both termini were relatively stable and less susceptible to degradation and reduced purification yield.

[0465] Study 4: Large-scale protein yield and stability

[0466] Most recombinant proteins expressed as soluble proteins and purified under non-denaturing conditions have relatively high yields of their final products (>10 mg / L culture). Some of them even achieved yields exceeding 20 mg / L culture.

[0467] When purified from inclusion bodies or from soluble fractions under conditions intended to denature them (e.g., urea), the yields of these same recombinant proteins were much lower (2.1-3.6 mg / L culture). It should be noted that denatured proteins have low binding affinity to Ni affinity resins under denaturing conditions and low solubility when finally equilibrated in non-denaturing buffer. In addition, variants purified from their denatured forms were unstable in non-buffered saline, regardless of whether the protein was originally expressed as a soluble protein or an insoluble form, and whether it was purified using a pre-packed column or a loose Ni-NTA resin. These results suggest that it may be desirable to reduce or avoid the use of denaturants where they are not needed.

[0468] Low expression temperatures at 16°C were shown to be effective in improving soluble expression of proteins such as KDAK1 (SEQ ID NO: 56). For these proteins, purification bypassing the anion exchange step resulted in higher yields, for example, the yield of KDAK1 was doubled when produced in this manner. KDAK1n (SEQ ID NO: 55) was also found to be expressed as a soluble protein.

[0469] Although His staining of the gel confirmed degradation in regions containing multiple KAS (K) residues, no negative impact of Ni affinity chromatography on yield was observed. For example, the two protective antigens KKDAK1nKK (SEQ ID NO: 60) and KDAK1nK-4S-AVQP (SEQ ID NO: 53) had more than 90% of the expected full-length protein species in their final products, with yields ranging from 12-21 mg / L culture.

[0470] Reducing conditions were found to be beneficial for the extraction of insoluble KDcAK1n from inclusion bodies using urea. Higher concentrations of urea were required under non-reducing conditions than under reducing conditions. Apparently, the formation of disulfide bonds under denaturing conditions has an adverse effect on protein solubility. Interestingly, native PAGE gel analysis of the KDcAK1n chimera relative to a chimera in which all four cysteine ​​residues were mutated to serine (SEQ ID NO: 50) showed that the elimination of disulfide bonds in the mutated KDcAK1n chimera caused clearer ladder formation on native PAGE, which is consistent with the occurrence of only β-chain exchange multimerization. In addition, under the same non-reducing denaturing conditions, the chimeric mutant KDcAK1n PVQN>AVQP / 4Cys>Ser variant (SEQ ID NO: 51) was more soluble in urea than KDcAK1n.

[0471] When the proteins were expressed under the same conditions, the C-terminal His tag had no significant effect on protein production and solubility.

[0472] In the purification of the tag-free candidates, although anion exchange chromatography enriched the target protein, this step was not able to effectively separate the target protein from the E. coli host due to the tight binding affinity to the resin, as most E. coli proteins are acidic in the pI range of 4-7, many of which are close to the pI of the target protein. Interestingly, however, size exclusion chromatography at room temperature with 1M (NH4)2SO4 buffer appeared to be the key step and provided a method for efficient separation of the target protein from the E. coli target protein. After further purification by hydrophobic interaction and a second round of size exclusion chromatography, both lead tag-free candidates were purified to 99% purity with high homogeneity, as demonstrated by SDS- / native PAGE and SEC-MALS analysis.

[0473] Table 3: Summary of recombinant Kgp chimeras and fragments expressed in E. coli

[0474]

[0475]

[0476] Example 3: Animal research

[0477] Porphyromonas gingivalis prevents bone loss in a mouse model of periodontitis

[0478] 1. Experiment 1

[0479] Antigens tested: KDcAK1n 50 μg; KDcAK1n 0.5 μg; KDAK1 50 μg; KDAK1 0.5 μg. All antigens were absorbed onto alum in PBS (pH 7.4).

[0480] KDcAK1n: from inclusion bodies, batch purified with Ni-NTA resin followed by dialysis into 2M urea PBS under non-reducing conditions.

[0481] KDAK1: From the soluble fraction, Ni affinity (prepacked column) and anion exchange chromatography with gradient elution under non-reducing conditions followed by dialysis into PBS.

[0482] Porphyromonas gingivalis-induced alveolar bone loss in the maxilla of mice

[0483] At both concentrations tested, KDcAK1n protected against bone loss in an animal model (not shown).

[0484] Antibody response

[0485] Serum antibody subclass responses of immunized mice in the periodontitis model were detected by ELISA. Antisera were used to detect heat-inactivated Porphyromonas gingivalis strain W50 as the absorbed antigen. Antibody responses are expressed as three times the ELISA titer obtained minus the background level, where each titer represents the mean ± sd of 10 individual mice (data not shown). KDcAK1n induced the strongest total IgG and IgG1 responses against whole cells of Porphyromonas gingivalis, followed by KDAK1. At 50 μg, there were no significant differences in IgG and IgG1 antibody responses between the antigens tested.

[0486] 2. Experiment 2

[0487] Antigens tested: KDcAK1n 50 μg; KDcAK1n 0.5 μg; KDAK1 50 μg; KDAK1 0.5 μg. All antigens were adsorbed onto alum in saline (pH 7.4).

[0488] The antigen was purified in the same manner as in Experiment 1.

[0489] Porphyromonas gingivalis-induced alveolar bone loss in the maxilla of mice

[0490] This experiment examined the same antigen as Experiment 1; however, it was adsorbed onto the alum using saline rather than PBS. The bone loss results mirrored Experiment 1 (data not shown), where only KDcAK1n showed protection, indicating that using PBS or saline for alum preparation had no effect on the experimental results.

[0491] Antibody response

[0492] All antigens tested induced similar total IgG and IgG1 responses against whole-cell P. gingivalis. KDAK1 induced a stronger IgG2a response compared to KDcAK1n (not shown).

[0493] 3. Experiment 3

[0494] Antigens tested: All antigens except KDcAK1n were fractionated as described: KDcAK1n (dimer); KDcAK1n (multimer); KDcAK1n (prior art chimera); KDcAK1n-4S-AVQP.

[0495] KDcAK1n-4S-AVQP, KDcAK1n dimers and multimers: urea extraction from inclusion bodies, Ni affinity column purification, followed by gel filtration (two KDcAK1n samples were used under reducing conditions).

[0496] KDcAK1n: Purified according to Experiment 1.

[0497] Prescreening of vaccine candidates using mAbs directed against Porphyromonas gingivalis epitopes

[0498] To develop a pre-screening assay to determine the suitability of the antigens for animal models, the antigens were screened by ELISA using mAbs against KAS2, ABM2, ABM3, and EP1. All vaccine candidates were able to bind to the KAS2, ABM3, and EP1 mAbs, with large titration curves visible compared to the negative control muBM4 mAb. While KDcAK1n and KDcAKln-4S-AVQP bound to the ABM2 mAb, KDcAK1n dimers and KDcAK1n multimers did not bind - indicating that the epitope recognized by this mAb is inaccessible in these constructs (not shown).

[0499] Porphyromonas gingivalis-induced alveolar bone loss in the maxilla of mice

[0500] KDcAK1n-4S-AVQP provides modest protection against P. gingivalis-induced bone loss ( Figure 4 ), although to a different extent than KDcAK1n.

[0501] Antibody response

[0502] Serum antibody subclass responses of immunized mice in the periodontitis model were examined by ELISA. Antisera were used to probe heat-killed P. gingivalis strain W50 as adsorbed antigen. All antigens tested generated varying degrees of IgG responses. KDcAK1n multimers generated a strong IgG1 isotype response.

[0503] Analysis of non-protective purified dimer and multimer antigens

[0504] Analysis of the individual KDA dimer and multimer species purified without protection by anion exchange and gel filtration in Experiment 3 using reducing and non-reducing native and SDS PAGE revealed that in both cases the purified individual species were disulfide cross-linked denatured domains (disulfides locked into stable species). This analysis explains why these molecular weight species are stable and can be purified by anion exchange and gel filtration chromatography.

[0505] 4. Experiment 4

[0506] Antigens tested: KKDA1nKK; KDAK1n; KDAK1nK-4S-AVQP.

[0507] All antigens except KDAK1nK-4S-AVQP were purified from the soluble fraction using Ni affinity column, anion exchange and gel filtration chromatography under non-reducing conditions without the use of anion exchange chromatography.

[0508] alum absorption

[0509] The ability of the 2% hydrogel to absorb antigen was tested by incubating the antigen with alum for 60 minutes at 4°C and gently mixing. The alum was pelleted and then a Bradford protein assay was performed on the antigen before and after alum adsorption. The percentage of all antigens bound to alum was 91.7% to 99.3%. SDS-PAGE gels were also run on samples before and after alum adsorption and were consistent with the Bradford assay protein determination.

[0510] Prescreening of vaccine candidates using mAbs directed against Porphyromonas gingivalis epitopes

[0511] All vaccine candidates were able to bind to KAS2, ABM3 and EP1 mAbs, with large titration curves visible compared to the negative control muBM4 mAb. While KDAK1nK-4S-AVQP bound to the ABM2 mAb, KKDA1nKK and KDAK1n did not bind - indicating that the epitope recognized by this mAb is inaccessible in these constructs (not shown).

[0512] Porphyromonas gingivalis-induced alveolar bone loss in the maxilla of mice

[0513] KKDAK1nKK and KDAK1nK-4S-AVQP protect against Porphyromonas gingivalis-induced bone loss ( Figure 5 ).

[0514] Antibody response

[0515] Serum antibody subclass responses of immunized mice in a periodontitis model were examined by ELISA. Antisera were used to probe heat-killed P. gingivalis strain W50 as adsorbed antigen. All antigens tested produced varying degrees of IgG responses. Protective KKDAK1nKK induced robust total IgG and IgG1 responses against heat-killed P. gingivalis. Interestingly, KDAK1nK-4S-AVQP (which protected against bone loss) had a lower antibody response to whole-cell P. gingivalis compared to some of the weaker antigens.

[0516] Pooled serum samples were used to probe P. gingivalis domains adsorbed onto ELISA plates. All antigens generated total IgG responses to ABM21 (multimers and dimers) and ABM213 (multimers and dimers) to varying degrees. IgG responses to DUF2436 were only evident in antigens containing the complete DUF domain (KKDAK1nKK, KDAK1n, and KDAK1nK-4S-AVQP). Pooled serum samples were also used to probe P. gingivalis epitope peptides, and similarly no clear pattern between protection and non-protection was observed despite a clear trend toward high KAS titers in the protective antisera.

[0517] 5. Experiment 5

[0518] Antigen tested

[0519] All antigens were purified using Ni affinity chromatography under non-reducing conditions followed by dialysis into saline.

[0520] KDcAK1n - from inclusion bodies using urea and purified affinity column (IB, urea, AC); KDAK1 - from soluble fraction using urea and purified affinity column (S, urea, AC); KDAK1 - from inclusion bodies using urea and purified affinity column (IB, urea, AC); KDAK1 - from inclusion bodies using urea and purified affinity column (IB, urea, AC); KDAK1 - from inclusion bodies using urea and batch purification method (IB, urea, batch).

[0521] Prescreening of vaccine candidates with mAbs directed against Porphyromonas gingivalis epitopes.

[0522] All candidates were able to bind to KAS2, ABM3 and EP1 mAbs, with large titration curves visible compared to the negative control muBM4 mAb. None of the antigens bound to the ABM2 mAb, indicating that the epitope recognized by this mAb is inaccessible in these constructs (not shown).

[0523] Porphyromonas gingivalis-induced alveolar bone loss in the maxilla of mice

[0524] KDcAK1n(IB, urea, AC), KDA(S, AC), KDAK1(S, urea, AC), KDAK1(IB, urea, AC), and KDAK1(IB, urea, batched) showed significant protection against bone loss, with KDcAK1n(IB, urea, AC), KDA(S, AC), and KDAK1(IB, urea, batched) providing the best protection. Figure 6 ).

[0525] Notably, unfractionated affinity-purified antigens provided protection against bone loss, with good protection observed with affinity-purified soluble KDA in particular, but this protection was partially lost when treated with urea under oxidative conditions, which promotes disulfide cross-linking of denatured D and A domains. These results again suggest that disulfide cross-linking of denatured domains may abrogate antigen-induced protection, and therefore urea should be avoided and preparation of soluble folded domains should be preferred.

[0526] 6. Experiment 6

[0527] Antigen tested

[0528] All antigens were purified using Ni affinity chromatography under non-reducing conditions followed by dialysis into saline. Antigens tested were: KDcAK1n-from inclusion bodies using urea and purified affinity columns (IB, urea, AC); KDAK1nK, KDAK1n-4S-AVQP and KKDAK1nKK.

[0529] Porphyromonas gingivalis-induced alveolar bone loss in the maxilla of mice

[0530] All antigens tested protected against P. gingivalis-induced bone loss ( Figure 7 ).

[0531] Summary and discussion of the results presented in Examples 2 and 3

[0532] The work described in this report compared the production and efficacy of various vaccine candidates to identify components of the chimeric vaccine that could facilitate ease of production (e.g., components that aid in improving solubility, stability, and reducing propensity to multimerize) and that would be most effective in eliciting an immune response to Porphyromonas gingivalis and / or reducing Porphyromonas gingivalis-induced alveolar bone loss.

[0533] Although effective in preventing periodontal bone loss in an animal periodontitis model, the prior art vaccine KDcAK1n is expressed by E. coli as inclusion bodies and exhibits variable solubility and stability.

[0534] KDcAK1n is based on the fusion between the active site sequence (KAS or K) of the Lys-specific gingival protease Kgp and the processed adhesin fragment (A1) of the Kgp polyprotein. It is now clear from the structural analysis of the Kgp polyprotein domain that the A1 adhesin fragment found on the cell surface includes three discrete structural domains, namely the DUF domain (D), the ABM domain (A) and the K1 domain (K1). The processing of the Kgp polyprotein on the surface of Porphyromonas gingivalis to release the protease catalytic domain and adhesin involves a 38 amino acid residue truncation of the N-terminus of the DUF domain. These additional N-terminal 38 residues were added to the construct to produce a complete DUF domain instead of a truncated domain (Dc), resulting in a highly soluble recombinant protein.

[0535] KDcAK1n contains four cysteine ​​residues, one in DUF, two in ABM, and one in K1. These cysteine ​​residues are responsible for the problems leading to inclusion body formation. Porphyromonas gingivalis is an obligate anaerobe and requires a highly reducing environment to be pathogenic. Known or modeled structures of the Kgp domains indicate that the cysteine ​​residues are reduced on the cell surface and do not participate in disulfide bonds. Expression in E. coli under more oxidizing conditions causes the formation of disulfide bridges between the denatured domains and the formation of inclusion bodies. The disulfide bridges between the denatured domains of the chimera can be seen on non-reducing native PAGE (which changes upon reduction).

[0536] The results presented here indicate that the folded ABM domain of Kgp multimerizes via β-strand exchange to form a uniform ladder independent of reducing agents ( Figure 3 gingivalis to form a surface layer of gingipains that are released not only on the cell but also into the outer membrane vesicles in the host during disease progression. This work characterizing the prior art chimera KDcAK1n and domains clearly demonstrated that two forms of multimers were present in the original chimera; multimers based on disulfide bridged denatured domains and multimers based on beta-strand exchanged native ABM domains. Attempts to separate and purify these different forms into specific dimers and larger molecular weight multimers were unsuccessful. Furthermore, the use of these different purified single species did not result in protection against periodontal bone loss in animal models due to the fact that they were disulfide locked denatured structures ( Figure 4 ). This work demonstrated that a soluble, well-defined, and homogeneous reconstitution of the domains with folded D and A without disulfide crosslinks would be superior to a mixture of denatured and native forms, which was generated in lower yields by solubilizing the chimera from inclusion bodies in 8 M urea ( Figure 7 ).

[0537] These results suggest that the presence of cysteine ​​residues in the antigen may pose problems for solubility and expression and purification of established commercially developed candidates. The possibility of mutating these cysteine ​​residues to serine was therefore explored. Mutating the four cysteine ​​residues to four serine residues did not prevent the ABM(A) native domain β-strand crossover multimerization, indicating that the ABM domain is still correctly folded in the "4C" to "4S" mutant ( Figure 3 ).

[0538] Furthermore, these results suggest that mutation of the Pro hinge elbow in the critical sequence of the ABM domain, predicted to allow β-strand flipping (PVQN>AVQP), abolishes β-strand exchange multimerization ( Figure 3 Thus, the combination of mutation of the four Cys residues to Ser and mutation of the hinge region PVQN to AVQP abolished multimerization under both oxidative and reductive conditions ( Figure 3 In this regard, the mutant KDAK1nK-4S-AVQP protected against periodontal bone loss and generated good antibody titers against predicted protective epitopes (KAS, DUF, ABM) in an animal periodontitis model ( Figure 5 ).

[0539] Examination of antibody responses to different segments of the chimera (K, D, A and K1) and suspected important epitopes (KAS, ABM2, ABM3, EP1) using protective and non-protective sera did not provide any clear pattern, although it was clear that these protected chimera variants tended to show strong (IgG / IgG1) responses to intact P. gingivalis cells as well as to known protective epitopes (KAS, DUF, ABM), so it appears that protection may not be related to any one epitope but more to the combination of epitopes required to ensure adequate protection against periodontal bone loss. However, there was a trend for one epitope to stand out, involving the active site sequence KAS of the chimera variants that provided protection.

[0540] Although there is no clear indication that either epitope is more important and therefore responses to this epitope can be used as a surrogate or biomarker for vaccine-induced protection, it is clear that the protective chimeric variants tend to generate good antibody responses to the protease active site sequence (KAS or K). It has been previously demonstrated that antibodies generated against the active site sequence can neutralize the proteolytic activity of gingipains (Kgp and RgpA / B), which are the major virulence factors of Porphyromonas gingivalis. Therefore, in order to increase antibody titers against the active site and thereby enhance protection, the inventors added an additional copy of the active site sequence (K), and both KDAK1n and this construct showed improved protection in an animal periodontitis model ( Figure 6). The soluble non-multimerizing mutant KDAK1nK-4S-AVQP, which has two copies of the KAS(K) motif, has good protection against Porphyromonas gingivalis-induced periodontal bone loss. ( Figure 6 ).

Claims

1. A chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis (P. gingivalis), the protein comprising a first polypeptide and a second polypeptide, wherein: A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis; wherein the second polypeptide comprises one or more adhesin binding motif (ABM) sequences, and wherein the second polypeptide comprises part or all of the sequence of a cleaved adhesin domain (CAD), and wherein: a) the second polypeptide comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain or a sequence at least 80% identical thereto; b) said second polypeptide comprises one or more cysteine ​​amino acid substitutions in said adhesin domain compared to the naturally occurring Arg-gingipain or Lys-gingipain sequence in the corresponding region; and c) the second polypeptide comprises one or more amino acid motif substitutions selected from the group consisting of: i) substitution of proline and / or asparagine residues in the sequence PxxN corresponding to residues 6 to 9 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at positions equivalent to said residues; ii) a substitution of the motif NxFA to SxYQ in the sequence corresponding to residues 2 to 5 of the sequence of SEQ ID NO: 14 or 19 (ABM1) or at a position equivalent to said residues; iii) the substitution of a second tyrosine residue corresponding to, or equivalent to, the residue at position 5 of SEQ ID NO: 15 or 20 (ABM2) and a tryptophan residue corresponding to, or equivalent to, the residue at position 23 of SEQ ID NO: 14 or 19 (ABM1) into an alanine residue.

2. The chimeric or fusion protein of claim 1, wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 20, SEQ ID NO: 14 or 19 and / or SEQ ID NO: 17 or 21, or a sequence at least 80% identical thereto.

3. The chimeric or fusion protein of claim 1 or 2, wherein the one or more ABMs comprise a sequence as set forth in any one of SEQ ID NO: 16 or SEQ ID NO: 18 or 22, or a sequence at least 80% identical thereto.

4. The chimeric or fusion protein according to any one of claims 1 to 3, wherein the second polypeptide comprises part or all of the sequence of CAD having the amino acid sequence shown in SEQ ID NO: 12 or 13 or a sequence at least 80% identical thereto.

5. The chimeric or fusion protein of any one of claims 1 to 4, wherein the amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain is a sequence that accounts for at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the length of the DUF2436 domain of Arg-gingipain or Lys-gingipain.

6. The chimeric or fusion protein of claim 5, wherein the amino acid sequence of the DUF2436 domain of Arg-gingipain or Lys-gingipain is the sequence shown in SEQ ID NO:23, or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

7. The chimeric or fusion protein of any one of claims 1 to 6, wherein the second polypeptide comprises the sequence shown in SEQ ID NO:33, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

8. The chimeric or fusion protein of any one of the preceding claims, wherein the second polypeptide does not comprise a substitution of a cysteine ​​residue in the DUF2436 domain.

9. The chimeric or fusion protein of any one of claims 1 to 7, wherein the second polypeptide comprises a substitution of a cysteine ​​residue in the DUF2436 domain.

10. The chimeric or fusion protein of claim 9, wherein the substitution of the cysteine ​​residue is a substitution of a serine or valine residue.

11. The chimeric or fusion protein of claim 10, wherein the substitution of the cysteine ​​residue is a substitution of a serine residue.

12. The chimeric or fusion protein of any one of claims 1 to 11, wherein the second polypeptide comprises a substitution of one or more of the cysteine ​​residues in the ABM domain.

13. The chimeric or fusion protein of claim 12, wherein the substitution of the one or more cysteine ​​residues is a substitution of a serine residue or a valine residue.

14. The chimeric or fusion protein of claim 13, wherein the substitution of the one or more cysteine ​​residues is a substitution of a serine residue.

15. The chimeric or fusion protein of any one of claims 12 to 14, wherein the sequence of one or more ABM domains is shown in SEQ ID NO: 18 or 22, and wherein the one or more cysteine ​​residues correspond to the residues at positions 36 and 50 of SEQ ID NO: 18 or 22.

16. A chimeric or fusion protein according to any one of the preceding claims, wherein the second polypeptide comprises a substitution of a proline and / or asparagine residue in the sequence PxxN of the ABM1 of the Porphyromonas gingivalis adhesin domain corresponding to residues 6 to 9 of the sequence of SEQ ID NO: 14 or 19 or at a position equivalent to said residues.

17. The chimeric or fusion protein of claim 16, wherein the second polypeptide comprises the sequence AxxN, AxxA or AxxP in ABM1 corresponding to residues 6 to 9 of the sequence of SEQ ID NO: 14 or 19 or located at positions equivalent to said residues.

18. The chimeric or fusion protein of any one of the preceding claims, wherein the second polypeptide comprises or consists of an amino acid sequence as shown in any one of SEQ ID NOs: 33 to 48.

19. The chimeric or fusion protein of claim 18, wherein the second polypeptide comprises or consists of the amino acid sequence shown in SEQ ID NO: 39 or 40.

20. The chimeric or fusion protein of claim 17, wherein the second polypeptide comprises or consists of the amino acid sequence shown in SEQ ID NO: 47 or 48.

21. The chimeric or fusion protein of any one of claims 1 to 15, wherein the second polypeptide comprises a substitution of the motif NxFA to SxYQ in the ABM1 of the Porphyromonas gingivalis adhesin domain corresponding to or at positions equivalent to residues 2 to 5 of SEQ ID NO: 14 or 19.

22. The chimeric or fusion protein of any one of claims 1 to 15, wherein the second polypeptide comprises a second tyrosine residue corresponding to or equivalent to the residue at position 5 of ABM2 and a substitution of a tryptophan residue corresponding to or equivalent to the residue at position 23 of ABM1 into an alanine residue.

23. The chimeric or fusion protein of any one of claims 1 to 22, wherein the first polypeptide is linked to the second polypeptide.

24. The chimeric or fusion protein of any one of claims 1 to 23, wherein the first polypeptide is located at the N-terminus of the second polypeptide.

25. The chimeric or fusion protein of any one of claims 1 to 24, wherein the first polypeptide is directly conjugated to the second polypeptide.

26. The chimeric or fusion protein of any one of claims 1 to 24, wherein the first polypeptide is linked to the second polypeptide via a linker.

27. The chimeric or fusion protein of claim 26, wherein the linker is a peptide linker.

28. The chimeric or fusion protein of claim 27, wherein the peptide linker comprises at least 2 amino acids, at least 5 amino acids, at least 10 amino acids, at least 15 amino acids, at least 20 amino acids, preferably wherein the linker comprises no more than 50 amino acids.

29. The chimeric or fusion protein of claim 27 or 28, wherein the peptide linker is no more than 25 amino acids, no more than 20 amino acids, no more than 15 amino acids, or no more than 10 amino acids.

30. The chimeric or fusion protein of any one of claims 1 to 29, wherein the first polypeptide comprises or consists of an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 11, or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

31. The chimeric or fusion protein of claim 30, wherein the first polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1 or 2, or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

32. The chimeric or fusion protein of any one of claims 1 to 31, wherein the chimeric or fusion protein comprises one or more additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto.

33. The chimeric or fusion protein of claim 32, wherein the one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis are located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide, the C-terminus of the second polypeptide.

34. The chimeric or fusion protein of claim 33, wherein the one or more additional polypeptides are directly linked to the first polypeptide or the second polypeptide of the chimeric or fusion protein.

35. The chimeric or fusion protein of claim 34, wherein the one or more additional polypeptides are linked to the first polypeptide or the second polypeptide via a peptide linker.

36. The chimeric or fusion protein of claim 35, wherein the peptide linker comprises at least 2 amino acids, at least 5 amino acids, at least 10 amino acids, at least 15 amino acids, at least 20 amino acids, preferably wherein the linker comprises no more than 50 amino acids.

37. The chimeric or fusion protein of claim 35 or 36, wherein the peptide linker is no more than 25 amino acids, no more than 20 amino acids, no more than 15 amino acids, or no more than 10 amino acids.

38. The chimeric or fusion protein according to any one of claims 32 to 37, wherein the one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of: SEQ ID NO: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

39. The chimeric or fusion protein of claim 37, wherein the first polypeptide and the one or more additional polypeptides are identical or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each other.

40. The chimeric or fusion protein of claim 38, wherein the first polypeptide and the one or more additional polypeptides comprise the amino acid sequence of the active site of a heterologous gingipain from Porphyromonas gingivalis.

41. The chimeric or fusion protein of claim 38, wherein the first polypeptide and the one or more additional polypeptides comprise the amino acid sequence of the active site of Lys-gingipain.

42. The chimeric or fusion protein of claim 38, wherein the first polypeptide comprises the amino acid sequence of the active site of Lys-gingipain and the one or more additional polypeptides comprise the amino acid sequence of the active site of Arg-gingipain.

43. The chimeric or fusion protein of any one of claims 1 to 42, wherein the chimeric or fusion protein comprises or consists of the amino acid sequence as shown in any one of SEQ ID NO: 52 or 53, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% thereof.

44. The chimeric or fusion protein of any one of claims 1 to 43, wherein the protein comprises additional amino acid residues to facilitate expression in a recombinant expression system and / or to facilitate purification of the protein.

45. The chimeric or fusion protein of claim 44, wherein the additional amino acids comprise one, two, three, four or five amino acids in the N-terminal region, optionally including an N-terminal methionine and / or alanine.

46. ​​The chimeric or fusion protein of claim 44 or 45, wherein the additional amino acids comprise one, two, three, four or five amino acids in the C-terminal region.

47. A nucleic acid encoding the chimeric or fusion protein of any one of claims 1 to 46.

48. A vector or construct comprising the nucleic acid according to claim 47.

49. A host cell comprising the nucleic acid of claim 47 or the vector or construct of claim 48.

50. A composition comprising the chimeric or fusion protein of any one of claims 1 to 46.

51. The composition of claim 50, wherein the composition is a vaccine composition and comprises one or more adjuvants for enhancing the immune response to the chimeric or fusion protein.

52. A vaccine or immunostimulatory composition comprising a chimeric or fusion protein according to any one of claims 1 to 46 and optionally an adjuvant for enhancing the immune response to the chimeric or fusion protein.

53. A method for inducing an immune response to Porphyromonas gingivalis in a subject, the method comprising administering to a subject in need thereof a chimeric or fusion protein according to any one of claims 1 to 46, a composition according to claim 50 or 51, or a vaccine or immunostimulatory composition according to claim 52.

54. A method of inducing a humoral immune response to Porphyromonas gingivalis in a subject, the method comprising administering to the subject a chimeric or fusion protein according to any one of claims 1 to 46, a composition according to claim 50 or 51, or a vaccine or immunostimulatory composition according to claim 52.

55. The method of claim 54, wherein the induced immune response comprises a switch from a Th1 to a Th2 immune response.

56. A method of immunizing a subject against infection by Porphyromonas gingivalis, the method comprising administering to the subject a chimeric or fusion protein according to any one of claims 1 to 46, a composition according to claim 50 or 51, or a vaccine or immunostimulatory composition according to claim 52.

57. A method of treating a Porphyromonas gingivalis infection in a subject, the method comprising administering to a subject in need thereof a chimeric or fusion protein according to any one of claims 1 to 46, a composition according to claim 50 or 51, or a vaccine or immunostimulatory composition according to claim 52.

58. A method for reducing or minimizing the severity of symptoms associated with Porphyromonas gingivalis infection, the method comprising administering to an individual in need thereof a chimeric or fusion protein according to any one of claims 1 to 46, a composition according to claim 50 or 51, or a vaccine or immunostimulatory composition according to claim 52, Wherein the symptom is selected from the group consisting of: swollen or puffy gums, gums that bleed easily, receding gums, periodontal pockets around the teeth, loss of tissue supporting the teeth (periodontal ligament, cementum and / or alveolar bone), pus between the gums and teeth, and gingivitis.

59. The method of claim 57 or 58, wherein the method further comprises administering one or more of: an antimicrobial compound, an anti-inflammatory agent.

60. Use of a chimeric or fusion protein according to any one of claims 1 to 46 for the preparation of a medicament for: ●inducing an immune response to Porphyromonas gingivalis in a subject; ●Immunize subjects against Porphyromonas gingivalis infection; ● Treating a subject for a Porphyromonas gingivalis infection; or - Minimizing or reducing the severity of one or more symptoms of a Porphyromonas gingivalis infection.

61. The chimeric or fusion protein of any one of claims 1 to 46, the composition of claim 50 or 51, or the vaccine or immunostimulatory composition of claim 52, for use in: ●inducing an immune response to Porphyromonas gingivalis in a subject; ●Immunize subjects against Porphyromonas gingivalis infection; ● Treating a subject for a Porphyromonas gingivalis infection; or - Minimizing or reducing the severity of one or more symptoms of a Porphyromonas gingivalis infection.

62. A method for obtaining antibodies against Porphyromonas gingivalis, the method comprising administering to a non-human animal a chimeric or fusion protein according to any one of claims 1 to 46, a composition according to claim 50 or 51, or a vaccine or immunostimulatory composition according to claim 52, thereby producing antibodies against Porphyromonas gingivalis in the animal.

63. The method of claim 62, wherein the method further comprises isolating the antibody from the animal or an egg of the animal.

64. An antibody preparation comprising antibodies against Porphyromonas gingivalis, wherein the antibody preparation is obtained by administering a chimeric or fusion protein according to any one of claims 1 to 46, a composition according to claim 50 or 51, or a vaccine or immunostimulatory composition according to claim 52 to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal, and isolating the antibodies from the animal or its eggs.

65. A kit comprising a composition comprising a chimeric or fusion protein according to any one of claims 1 to 46, a composition according to claim 50 or 51, or a vaccine or immunostimulatory composition according to claim 3523, wherein optionally the kit comprises one or more cytokines and / or adjuvants in a sealed container, preferably wherein the kit comprises a label or package insert indicating that the composition is for immunizing an individual, optionally wherein the label or package insert comprises instructions for use.